



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>7</sup> :</b> <b>C07D 211/58, 213/75, 211/96, 295/20, 295/18, 295/22, A61K 31/445, 31/496, A61P 25/28</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 00/42011</b> <b>(43) International Publication Date:</b> 20 July 2000 (20.07.00)
<b>(21) International Application Number:</b> PCT/JP00/00017 <b>(22) International Filing Date:</b> 6 January 2000 (06.01.00) <b>(30) Priority Data:</b> PP 8180 14 January 1999 (14.01.99) AU <b>(71) Applicant (for all designated States except US):</b> FUJISAWA PHARMACEUTICAL CO., LTD. [JP/JP]; 4-7, Doshomachi 3-chome, Chuo-ku, Osaka-shi, Osaka 541-8514 (JP). <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> YAMADA, Akira [JP/JP]; 4-8-30, Sawada, Fujiidera-shi, Osaka 583-0011 (JP). AOKI, Satoshi [JP/JP]; 2-38-3, Maborikaigan, Yokosuka-shi, Kanagawa 239-0801 (JP). <b>(74) Agent:</b> TABUSHI, Eiji; Fujisawa Pharmaceutical Co., Ltd., Osaka Factory, 1-6, Kashima 2-chome, Yodogawa-ku, Osaka-shi, Osaka 532-8514 (JP).		<b>(81) Designated States:</b> AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i>
<b>(54) Title:</b> AMIDE COMPOUNDS  <div style="display: flex; justify-content: space-around; align-items: center;"> <div style="text-align: center;"> <math display="block">  \begin{array}{c}  R^1-A-N-E \\    \quad   \\  R^3 \quad R^4  \end{array}  \begin{array}{c}  X-Y-Q-R^2 \\    \\  R^4  \end{array}  \quad (1)  </math> </div> <div style="text-align: center;"> <math display="block">  \begin{array}{c}  O \\     \\  -C-  \end{array}  \quad (1)  </math> </div> </div> <b>(57) Abstract</b>  <p>This invention relates to new amide compounds having the potentiation of the cholinergic activity, etc., and represented by general formula (I), wherein R<sup>1</sup> is acyl, R<sup>2</sup> is lower alkyl, etc., A is a single bond, (1) or -SO<sub>2</sub>-, E is lower alkylene, etc., X is CH or N, Y is a single bond, etc., Q is -CH<sub>2</sub>-, etc., and R<sup>3</sup> and R<sup>4</sup> are taken together to form lower alkylene, etc., and pharmaceutically acceptable salts thereof, to processes for preparation thereof and a pharmaceutical composition comprising the same.</p>		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

## DESCRIPTION

## AMIDE COMPOUNDS

## 5 TECHNICAL FIELD

This invention relates to new amide compounds and pharmaceutically acceptable salts thereof which are useful as a medicament.

## 10 BACKGROUND ART

Some aminopiperazine derivatives have been known as useful anti-amnesia or anti-dementia agents, for example, in PCT International Publication Nos. WO 91/01979 and WO 98/35951.

15

## DISCLOSURE OF INVENTION

This invention relates to new amide compounds and pharmaceutically acceptable salts thereof.

More particularly, it relates to new amide compounds and pharmaceutically acceptable salts thereof which have the  
20 potentiation of the cholinergic activity, to processes for the preparation thereof, to a pharmaceutical composition comprising the same, and to a method for the treatment and/or prevention of disorders in the central nervous system for  
25 mammals, and more particularly to method for the treatment and/or prevention of amnesia, dementia (e.g., senile dementia, Alzheimer's dementia, dementia associated with various diseases such as cerebral vascular dementia, cerebral post-traumatic dementia, dementia due to brain tumor, dementia due  
30 to chronic subdural hematoma, dementia due to normal pressure hydrocephalus, post-meningitis dementia, Parkinson's disease type dementia, etc.), and the like. Additionally, the object compound is expected to be useful as therapeutical and/or preventive agents for schizophrenia, depression, stroke, head  
35 injury, nicotine withdrawal, spinal cord injury, anxiety,

pollakiuria, incontinence of urine, myotonic dystrophy, attention deficit hyperactivity disorder, excessive daytime sleepiness (narcolepsy), Parkinson's disease or autism.


One object of this invention is to provide new and  
5 useful amide compounds and pharmaceutically acceptable salts thereof which possess the potentiation of the cholinergic activity.

Another object of this invention is to provide processes for preparation of said amide compounds and salts thereof.

10 A further object of this invention is to provide a pharmaceutical composition comprising, as an active ingredient, said amide compounds and pharmaceutically acceptable salt thereof.

Still further object of this invention is to provide a  
15 therapeutic method for the treatment and/or prevention of aforesaid diseases in mammals, using said amide compounds and pharmaceutically acceptable salts thereof.

The amide compounds of this invention are new and can be  
20 represented by the following general formula [I]:



25

wherein  $\text{R}^1$  is acyl,

30

$\text{R}^2$  is lower alkyl, lower alkoxy, lower alkylamino, lower alkenyl, lower alkenyloxy, lower alkenylamino, lower alkynyl, lower alkynyloxy, lower alkynylamino, cyclo(lower)alkyl, cyclo(lower)alkyloxy, cyclo(lower)alkylamino, aryl, aryloxy, arylamino, a heterocyclic group or amino substituted with a heterocyclic group, each of which may be substituted with suitable substituent(s); or acyl;

35

A is a single bond,  $\overset{\text{O}}{\parallel}\text{-C-}$  or  $\text{-SO}_2\text{-}$ ,

E is lower alkylene optionally substituted with suitable substituent(s),

5 X is CH or N,

Y is a single bond, lower alkylene or  $\overset{\text{R}^5}{\underset{|}{\text{N-}}}$   
(wherein  $\text{R}^5$  is hydrogen, lower alkyl,  
substituted-lower alkyl, an N-protective group,  
aryl, acyl or a heterocyclic group),

10 Q is  $\text{-CH}_2\text{-}$ ,  $\overset{\text{O}}{\parallel}\text{-C-}$ ,  $\text{-SO}_2\text{-}$  or  $\text{-N=CH-}$ , and

$\text{R}^3$  and  $\text{R}^4$  are each hydrogen or lower alkyl, or are  
taken together to form lower alkylene optionally  
condensed with a cyclic hydrocarbon or a  
15 heterocyclic ring,

provided that when X is N,

then 1) Y is a single bond, and

Q is  $\text{-CH}_2\text{-}$ ,  $\overset{\text{O}}{\parallel}\text{-C-}$  or  $\text{-SO}_2\text{-}$ , or


20 2) Y is lower alkylene,

and pharmaceutically acceptable salts thereof.


The object compound [I] or its salt can be prepared by  
processes as illustrated in the following reaction schemes.

25

### Process 1



+



30


[II]

or its salt

[III]


or its reactive derivative  
at the carboxy or sulfo  
group, or a salt thereof

35



[Ia]

or its salt


Process 2

[II]

or its salt


[Ib]

or its salt


Process 3

[V]

or its salt







[III]

or its reactive derivative  
at the carboxy or sulfo  
group, or a salt thereof

[Ic]

or its salt

Process 410 Process 5Process 6




5

[Ie]  
or its salt

Process 7

10



[X]

or its salt


[If]

or its salt

15

Process 8

20



[If]

or its salt


[Ig]

or its salt

25

Process 9

30



[Ih]



or its salt

[Ii]

or its salt

35



Process 10

wherein  $\text{R}^1$ ,  $\text{R}^2$ ,  $\text{R}^3$ ,  $\text{R}^4$ , A, E, Q, X and Y are each as defined above,

$\text{Q}_\text{a}$  is  $\text{-}\overset{\text{O}}{\parallel}\text{C-}$  or  $\text{-SO}_2\text{-}$ ,

$\text{R}^6$  is aryl which may be substituted with suitable substituent(s), or pyridyl,

$\text{R}^7$  is lower alkyl, lower alkenyl, lower alkynyl, cyclo(lower)alkyl, aryl or a heterocyclic group, each of which may be substituted with suitable substituent(s),

$\text{R}_\text{a}^5$  is an N-protective group,

$\text{R}_\text{a}^2$  is lower alkyl, lower alkenyl, lower alkynyl, cyclo(lower)alkyl, aryl or a heterocyclic group, each of which may be substituted with suitable substituent(s),

$\text{Q}_\text{b}$  is  $\text{-CH}_2\text{-}$ ,  $\text{-}\overset{\text{O}}{\parallel}\text{C-}$ , or  $\text{-SO}_2\text{-}$ ,

$\text{Z}_\text{a}$  is an acid residue,

$\text{Q}_\text{c}$  is  $\text{-}\overset{\text{O}}{\parallel}\text{C-}$ ,

$R_D^5$  is lower alkyl,  
 $Z_D$  is an acid residue,  
 $Z_C$  is an acid residue, and  
 $Y_a$  is lower alkylene.

5

In the above and subsequent description of the present specification, suitable examples of the various definitions to be included within the scope of the invention are explained in detail in the following.

10

The term "lower" is intended to mean a group having 1 to 6 carbon atom(s), unless otherwise provided.

The lower moiety in the term "lower alkenyl", "lower alkenyloxy", "lower alkenylamino", "lower alkynyl", "lower alkynyloxy" and "lower alkynylamino" is intended to mean a group having 2 to 6 carbon atoms.

The lower moiety in the terms "cyclo(lower)alkyl", "cyclo(lower)alkyloxy" and "cyclo(lower)alkylamino" is intended to mean a group having 3 to 6 carbon atoms.

Suitable "lower alkyl" and lower alkyl moiety in the terms "substituted-lower alkyl", "ar(lower)alkyl", "halo(lower)alkyl", "lower alkylamino", "lower alkylsilyl", "lower alkylthio" and "lower alkylsulfonyl" may be a straight or branched  $C_1$ - $C_6$  alkyl such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, pentyl, ethylpropyl, hexyl or the like, in which preferable one is methyl.

Suitable "lower alkenyl" and lower alkenyl moiety in the terms "lower alkenyloxy" and "lower alkenylamino" may be a straight or branched  $C_2$ - $C_6$  alkenyl such as ethenyl, propenyl, butenyl, pentenyl, hexenyl, isopropenyl, butadienyl, pentadienyl, hexadienyl or the like, in which preferable one is ethenyl, propenyl or butadienyl.

Suitable "lower alkynyl" and lower alkynyl moiety in the terms "lower alkynyloxy" and "lower alkynylamino" may be a straight or branched  $C_2$ - $C_6$  alkynyl such as ethynyl, propargyl,

butynyl or the like, in which preferable one is ethynyl.

Suitable "cyclo(lower)alkyl" and cyclo(lower)alkyl moiety in the terms "cyclo(lower)alkyloxy" and "cyclo(lower)alkylamino" may be cyclo(C<sub>3</sub>-C<sub>6</sub>)alkyl such as cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl, in which preferable one is cyclopropyl.

Suitable "aryl" and aryl or ar moiety in the terms "ar(lower)alkoxy", "aryloxy", "arylamino", "arylsulfonyl", "aroxy" and "ar(lower)alkyl" may be phenyl, naphthyl, phenyl substituted with lower alkyl [e.g. tolyl, xylyl, mesityl, cumenyl, di(tert-butyl)phenyl, etc.] and the like, in which preferable one is phenyl or tolyl.

Suitable "ar(lower)alkyl" may be benzyl, phenethyl, phenylpropyl, benzhydryl, trityl and the like, in which preferable one is benzyl.

Suitable "lower alkylene" and lower alkylene moiety in the term "lower alkylenedioxy" may be a straight or branched C<sub>1</sub>-C<sub>6</sub> alkylene such as methylene, ethylene, trimethylene, propylene, tetramethylene, pentamethylene, hexamethylene, ethylethylene or the like, in which preferable one is methylene, ethylene or trimethylene.

Suitable "lower alkoxy" and lower alkoxy moiety in the terms "ar(lower)alkoxy" and "halo(lower)alkoxy" may be a straight or branched C<sub>1</sub>-C<sub>6</sub> alkoxy such as methoxy, ethoxy, propoxy, isopropoxy, methylpropoxy, butoxy, isobutoxy, tert-butoxy, pentyloxy, hexyloxy or the like, in which preferable one is methoxy or tert-butoxy.

Suitable "ar(lower)alkoxy" may be benzyloxy, phenethyloxy, phenylpropoxy, benzhydryloxy, trityloxy and the like.

Suitable "halogen" and halo moiety in the term "halo(lower)alkyl" may be fluorine, chlorine, bromine and iodine, in which preferable one is fluorine, chlorine or iodine.

Suitable "halo(lower)alkyl" may be lower alkyl

substituted with one or more halogens such as chloromethyl, dichloromethyl, fluoromethyl, difluoromethyl, trifluoromethyl, pentachloroethyl or the like, in which preferable one is trifluoromethyl.

5        Suitable "halo(lower)alkoxy" may be lower alkoxy substituted with one or more halogens such as chloromethoxy, dichloromethoxy, fluoromethoxy, difluoromethoxy, trifluoromethoxy, pentachloromethoxy or the like, in which preferable one is trifluoromethoxy.

10       Suitable "lower alkylamino" may be mono or di(lower alkylamino) such as methylamino, ethylamino, propylamino, isopropylamino, butylamino, tert-butylamino, isobutylamino, pentylamino, hexylamino, dimethylamino, diethylamino, dipropylamino, dibutylamino, diisopropylamino, dipentylamino,  
15       dihexylamino, N-methylethylamino or the like, in which preferable one is dimethylamino.

      Suitable "lower alkylsilyl" may be mono, di, or tri(lower)alkylsilyl such as trimethylsilyl, dimethylsilyl, triethylsilyl or the like, in which preferable one is  
20       trimethylsilyl.

      Suitable "lower alkylenedioxy" may be methylenedioxy, ethylenedioxy and the like, in which preferable one is methylenedioxy.

      Suitable "heterocyclic group" may be one containing at  
25       least one hetero atom selected from nitrogen, sulfur and oxygen atom, and may include saturated or unsaturated, monocyclic or polycyclic heterocyclic group, and preferable heterocyclic group may be N-containing heterocyclic group such as unsaturated 3 to 6-membered heteromonocyclic group  
30       containing 1 to 4 nitrogen atoms, for example, pyrrolyl, pyrrolinyl, imidazolyl, pyrazolyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazolyl [e.g. 4H-1,2,4-triazolyl, 1H-1,2,3-triazolyl, 2H-1,2,3-triazolyl, etc.], tetrazolyl [e.g. 1H-tetrazolyl, 2H-tetrazolyl, etc.], etc.;  
35       saturated 3 to 7-membered heteromonocyclic group containing 1

to 4 nitrogen atoms [e.g. pyrrolidinyl, imidazolidinyl, piperidyl, piperazinyl, homopiperazinyl, etc.];

unsaturated condensed heterocyclic group containing 1 to 5 nitrogen atoms, for example, indolyl, isoindolyl, indolizinyl, benzimidazolyl, quinolyl, isoquinolyl, imidazopyridyl, indazolyl, benzotriazolyl, tetrazolo-pyridazinyl [e.g. tetrazolo[1,5-b]pyridazinyl, etc.], quioxaliny, etc.;

unsaturated 3 to 6-membered heteromonocyclic group containing an oxygen atom, for example, pyranyl, furyl, etc.;

saturated 3 to 6-membered heteromonocyclic group containing an oxygen atom, for example, 1H-tetrahydropyranyl, tetrahydrofuran, etc.;

unsaturated 3 to 6-membered heteromonocyclic group containing 1 to 2 sulfur atoms, for example, thienyl, etc.;

unsaturated 3 to 6-membered heteromonocyclic group containing 1 to 2 oxygen atoms and 1 to 3 nitrogen atoms, for example, oxazolyl, isoxazolyl, oxadiazolyl [e.g. 1,2,4-oxadiazolyl, 1,3,4-oxadiazolyl, 1,2,5-oxadiazolyl, etc.], oxazolinyl [e.g. 2-oxazolinyl, etc.], etc.;

saturated 3 to 6-membered heteromonocyclic group containing 1 to 2 oxygen atoms and 1 to 3 nitrogen atoms [e.g. morpholinyl, etc.];

unsaturated condensed heterocyclic group containing 1 to 2 oxygen atoms and 1 to 3 nitrogen atoms [e.g. benzofurazanyl, benzoxazolyl, benzoxadiazolyl, etc.];

unsaturated 3 to 6-membered heteromonocyclic group containing 1 to 2 sulfur atoms and 1 to 3 nitrogen atoms, for example, thiazolyl, thiadiazolyl [e.g. 1,2,4-thiadiazolyl, 1,3,4-thiadiazolyl, 1,2,5-thiadiazolyl, etc.], etc.;

saturated 3 to 6-membered heteromonocyclic group containing 1 to 2 sulfur atoms and 1 to 3 nitrogen atoms [e.g. thiazolidinyl, etc.];

unsaturated condensed heterocyclic group containing 1 to 2 sulfur atoms and 1 to 3 nitrogen atoms [e.g. benzothiazolyl,

benzothiadiazolyl, etc.];

unsaturated condensed heterocyclic group containing 1 to 2 oxygen atoms [e.g. benzofuranyl, benzodioxolyl, chromanyl, etc.] and the like.

5 Said "heterocyclic group" may be substituted with lower alkyl as exemplified above, in which preferable one is thienyl, pyridyl, methylpyridyl, quinolyl, indolyl, quinoxaliny, benzofuranyl or tetramethylchromanyl, and more preferable one is pyridyl.

10 Suitable "acyl" may be carboxy; esterified carboxy; carbamoyl substituted with lower alkyl, aryl, ar(lower)alkyl, arylsulfonyl, lower alkylsulfonyl or a heterocyclic group; substituted or unsubstituted arylsulfonyl; lower alkylsulfonyl; cyclo(lower)alkylcarbonyl;  
15 lower alkanoyl; substituted or unsubstituted aroyl; a heterocycliccarbonyl and the like.

The esterified carboxy may be substituted or unsubstituted lower alkoxy carbonyl [e.g. methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, butoxycarbonyl,  
20 tert-butoxycarbonyl, hexyloxycarbonyl, 2-iodoethoxycarbonyl, 2,2,2-trichloroethoxycarbonyl, etc.], substituted or unsubstituted aryloxy carbonyl [e.g. phenoxycarbonyl, 4-nitrophenoxycarbonyl, 2-naphthyloxycarbonyl, etc.], substituted or unsubstituted ar(lower)alkoxy carbonyl [e.g.  
25 benzyloxycarbonyl, phenethyloxycarbonyl, benzhydryloxycarbonyl, 4-nitrobenzyloxycarbonyl, etc.] and the like, in which preferable one is unsubstituted lower alkoxy carbonyl and more preferable one is methoxycarbonyl or tert-butoxycarbonyl.

30 The carbamoyl substituted with lower alkyl may be methylcarbamoyl, ethylcarbamoyl, propylcarbamoyl, dimethylcarbamoyl, diethylcarbamoyl, N-methyl-N-ethylcarbamoyl and the like.

The carbamoyl substituted with aryl may be  
35 phenylcarbamoyl, naphthylcarbamoyl, lower alkyl-substituted

phenylcarbamoyl [e.g. tolylcarbamoyl, xylylcarbamoyl, etc.] and the like.

The carbamoyl substituted with ar(lower)alkyl may be benzylcarbamoyl, phenethylcarbamoyl, phenylpropylcarbamoyl  
5 and the like, in which preferable one is benzylcarbamoyl.

The carbamoyl substituted with arylsulfonyl may be phenylsulfonylcarbamoyl, tolylsulfonylcarbamoyl and the like.

The carbamoyl substituted with lower alkylsulfonyl may be methylsulfonylcarbamoyl, ethylsulfonylcarbamoyl and the  
10 like.

The carbamoyl substituted with a heterocyclic group may be one substituted with a heterocyclic group as mentioned above.

15 The lower alkanoyl may be formyl, acetyl, propionyl, butyryl, isobutyryl, valeryl, isovaleryl, pivaloyl, hexanoyl and the like, in which preferable one is acetyl or pivaloyl.

The substituted or unsubstituted aroyl may be benzoyl, naphthoyl, toluoyl, di(tert-butyl)benzoyl,  
20 halo(lower)alkoxybenzoyl [e.g. trifluoromethoxybenzoyl, etc.] and the like, in which preferable one is benzoyl or trifluoromethoxybenzoyl.

The substituted or unsubstituted arylsulfonyl may be phenylsulfonyl, tolylsulfonyl, halophenylsulfonyl [e.g.  
25 fluorophenylsulfonyl, etc.] and the like, in which preferable one is fluorophenylsulfonyl.

The lower alkylsulfonyl may be methylsulfonyl, ethylsulfonyl and the like, in which preferable one is methylsulfonyl.

30 The cyclo(lower)alkylcarbonyl may be cyclo(C<sub>3</sub>-C<sub>6</sub>)-alkylcarbonyl such as cyclopropylcarbonyl, cyclobutylcarbonyl, cyclopentylcarbonyl or cyclohexylcarbonyl, in which preferable one is cyclopropylcarbonyl.

The heterocyclic moiety in the term  
35 "a heterocycliccarbonyl" may be one mentioned above as a

heterocyclic group.

Suitable "acid residue" may be halogen [e.g. fluoro, chloro, bromo, iodo], arenesulfonyloxy [e.g. benzenesulfonyloxy, tosyloxy, etc.], alkanesulfonyloxy [e.g. mesyloxy, ethanesulfonyloxy, etc.], and the like, in which preferable one is halogen.

Suitable "N-protective group" may be common N-protective group such as substituted or unsubstituted lower alkanoyl [e.g. formyl, acetyl, propionyl, trifluoroacetyl, etc.], lower alkoxycarbonyl [e.g. tert-butoxycarbonyl, tert-amylloxycarbonyl, etc.], substituted or unsubstituted aralkyloxycarbonyl [e.g. benzyloxycarbonyl, p-nitrobenzyloxycarbonyl, etc.], 9-fluorenylmethoxycarbonyl, substituted or unsubstituted arenesulfonyl [e.g. benzenesulfonyl, tosyl, etc.], nitrophenylsulfonyl, aralkyl [e.g. trityl, benzyl, etc.] or the like, in which preferable one is lower alkoxycarbonyl and more preferable one is tert-butoxycarbonyl.

Suitable "cyclic hydrocarbon" may be a saturated or unsaturated cyclic hydrocarbon such as cyclopentane, cyclohexane, benzene, naphthalene, indan, indene or the like.

Suitable "substituted-lower alkyl" may be lower alkyl substituted with halogen, aryl, acyl, lower alkoxy, aryloxy and the like, in which preferable one is benzyl.

Suitable "heterocyclic ring" may be one which is a heterocyclic group, as mentioned above, added by hydrogen.

Preferred "acyl" for  $R^1$  may be lower alkanoyl; lower alkoxycarbonyl; aroyl optionally substituted with halo(lower)alkoxy; arylsulfonyl optionally substituted with halogen; lower alkylsulfonyl; or cyclo(lower)alkylcarbonyl, in which more preferable one is acetyl, pivaloyl, methoxycarbonyl, tert-butoxycarbonyl, benzoyl, trifluoromethoxybenzoyl, fluorophenylsulfonyl, methylsulfonyl



or cyclopropylcarbonyl.

Preferred "suitable substituent" as the substituent of lower alkyl, lower alkoxy, lower alkylamino, lower alkenyl, lower alkenyloxy, lower alkenylamino, lower alkynyl, lower alkynyloxy, lower alkynylamino, cyclo(lower)alkyl, cyclo(lower)alkyloxy, cyclo(lower)alkylamine, aryl, aryloxy, arylamino, a heterocyclic group or amino substituted a heterocyclic group for  $R^2$  may be halo(lower)alkyl, halo(lower)alkoxy, lower alkenyl, lower alkynyl, lower alkylamino, acylamino, acyl, lower alkylsilyl, lower alkoxy, aryl, lower alkylenedioxy, acyloxy, hydroxy, nitro, amino, cyano, halogen, aryloxy, lower alkylthio and the like.

Preferred "aryl which may be substituted with suitable substituent(s)" for  $R^2$  may be aryl optionally substituted with halogen, in which more preferable one is fluorophenyl.

Preferred "aryl amino which may be substituted with suitable substituent(s)" for  $R^2$  may be aryl amino optionally substituted with halogen, in which preferable one is phenyl amino or fluorophenyl amino.

Preferred "aryloxy which may be substituted with suitable substituent(s)" for  $R^2$  may be aryloxy optionally substituted with halogen, in which preferable one is fluorophenoxy.

Preferred "lower alkylene" for Y may be methylene.

Preferred "lower alkyl" for  $R^5$  in Y may be methyl.

Preferred "N-protective group" for  $R^5$  in Y may be tert-butoxycarbonyl.

Preferred "suitable substituent" as the substituent of lower alkylene for E may be oxo, lower alkyl, hydroxy(lower)alkyl or acyl, in which more preferable one is oxo, dioxo, methyl, dimethyl, hydroxymethyl, or benzylcarbonyl.

Preferred "lower alkylene" for E may be methylene, ethylene or trimethylene, and more preferable one is ethylene.

Preferred "lower alkyl" for  $R^3$  and  $R^4$  may be methyl.

Preferred "lower alkylene which R<sup>3</sup> and R<sup>4</sup> are taken together to form" may be ethylene or trimethylene.

Preferred "a cyclic hydrocarbon with which lower alkylene is condensed" may be benzene.

5 Preferred compound [I] is one having lower alkanoyl, lower alkoxy carbonyl, aroyl, aroyl substituted with halo(lower)alkoxy, lower alkylsulfonyl, arylsulfonyl, arylsulfonyl substituted with halogen or cyclo(lower)alkylcarbonyl for R<sup>1</sup>, aryl, aryloxy or arylamino,  
10 each aryl of which may be substituted with halogen; pyridyl; or pyridylamino for R<sup>2</sup>, a single bond for

A, ethylene for E, CH for X,  $\begin{array}{c} \text{H} \\ | \\ -\text{N}- \end{array}$  for Y,  $\begin{array}{c} \text{O} \\ || \\ -\text{C}- \end{array}$  for Q, and  
15 ethylene for R<sup>3</sup> and R<sup>4</sup> to be taken together to form, or lower alkanoyl, lower alkoxy carbonyl, aroyl, aroyl substituted with halo(lower)alkoxy, lower alkylsulfonyl, arylsulfonyl, arylsulfonyl substituted with halogen or cyclo(lower)alkylcarbonyl for R<sup>1</sup>, aryl, aryloxy or arylamino,  
20 each aryl of which may be substituted with halogen; pyridyl; or pyridylamino for R<sup>2</sup>, a single bond for

A, ethylene for E, N for X, a single bond for Y,  $\begin{array}{c} \text{O} \\ || \\ -\text{C}- \end{array}$  for Q, and ethylene for R<sup>3</sup> and R<sup>4</sup> to be taken together to form.

Suitable pharmaceutically acceptable salts of the object  
25 compound [I] are conventional non-toxic salts and include acid addition salt such as an inorganic acid addition salt [e.g. hydrochloride, hydrobromide, sulfate, phosphate, etc.], an organic acid addition salt [e.g. formate, acetate, trifluoroacetate, maleate, tartrate, methanesulfonate,  
30 benzenesulfonate, toluenesulfonate, etc.], a salt with an amino acid [e.g. aspartic acid salt, glutamic acid salt, etc.], a metal salt such as an alkali metal salt [e.g. sodium salt, potassium salt, etc.] and alkaline earth metal salt [e.g. calcium salt, magnesium salt, etc.] and the like.

35

The processes for preparing the object compound [I] are explained in detail in the following.

#### Process 1

5       The compound [Ia] or its salt can be prepared by reacting a compound [II] or its salt with a compound [III] or its reactive derivative at the carboxy or sulfo group, or a salt thereof.

10       Suitable salts of the compounds [Ia] and [II] may be the same as those exemplified for the compound [I].

      Suitable salts of the compound [III] and its reactive derivative at the carboxy or sulfo group may be metal salt or alkaline earth metal salt as exemplified for the compound [I].

15       Suitable reactive derivative at the carboxy or sulfo group or the compound [III] may include an ester, an acid halide, an acid anhydride and the like. The suitable examples of the reactive derivatives may be an acid halide [e.g. acid chloride, acid bromide, etc.]; a symmetrical acid anhydride; a mixed acid anhydride with an  
20       acid such as aliphatic carboxylic acid [e.g. acetic acid, pivalic acid, etc.], substituted phosphoric acid [e.g. dialkylphosphoric acid, diphenylphosphoric acid, etc.]; an ester such as substituted or unsubstituted lower alkyl ester [e.g. methyl ester, ethyl ester, propyl ester, hexyl  
25       ester, trichloromethyl ester, etc.], substituted or unsubstituted ar(lower)alkyl ester [e.g. benzyl ester, benzhydryl ester, p-chlorobenzyl ester, etc.], substituted or unsubstituted aryl ester [e.g. phenyl ester, tolyl ester, 4-nitrophenyl ester, 2,4-dinitrophenyl ester,  
30       pentachlorophenyl ester, naphthyl ester, etc.], or an ester with N,N-dimethylhydroxylamine, N-hydroxysuccinimide, N-hydroxyphthalimide or 1-hydroxybenzotriazole, 1-hydroxy-6-chloro-1H-benzotriazole, or the like. These reactive derivatives can be optionally selected according to the kind  
35       of the compound [III] to be used.

The reaction is usually carried out in a conventional solvent such as water, acetone, dioxane, chloroform, methylene chloride, ethylene dichloride, tetrahydrofuran, acetonitrile, ethyl acetate, N,N-dimethylformamide, pyridine  
5 or any other organic solvent which does not adversely influence the reaction. Among these solvents, hydrophilic solvent may be used in a mixture with water.

The reaction is also preferably carried out in the presence of a conventional base such as triethylamine,  
10 diisopropylethylamine, pyridine, N,N-dimethylaminopyridine, etc., or a mixture thereof.

When the compound [III] is used in a free acid form or its salt form in the reaction, the reaction is preferably carried out in the presence of a conventional condensing  
15 agent such as N,N'-dicyclohexylcarbodiimide, N-cyclohexyl-N'-morpholinoethylcarbodiimide, N-ethyl-N'-(3-dimethylaminopropyl)carbodiimide, thionyl chloride, oxalyl chloride, lower alkoxy carbonyl halide [e.g. ethyl chloroformate, isobutyl chloroformate, etc.],  
20 1-(p-chlorobenzenesulfonyloxy)-6-chloro-1H-benzotriazole, or the like.

The reaction temperature is not critical, and the reaction can be carried out under cooling to heating.

## 25 Process 2

The compound [Ib] or its salt can be prepared by reacting a compound [II] or its salt with a compound [IV].

Suitable salts of the compounds [Ib] and [II] may be the same as those exemplified for the compound [I].

30 This reaction is usually carried out in a solvent such as dioxane, tetrahydrofuran, benzene, toluene, chloroform, methylene chloride or any other organic solvent which does not adversely influence the reaction.

The reaction temperature is not critical, and the  
35 reaction is usually carried out under cooling to warming.

Process 3

The compound [Ic] or its salt can be prepared by reacting a compound [V] or its salt with a compound [III] or its reactive derivative at the carboxy or sulfo group, or a salt thereof.

Suitable salts of the compounds [Ic] and [V] may be the same as those exemplified for the compound [I].

Suitable salts of the compound [III] and its reactive derivative at the carboxy or sulfo group may be metal salt or alkaline earth metal salt as exemplified for the compound [I].

This reaction can be carried out in substantially the same manner as Process 1, and therefore the reaction mode and reaction condition [e.g. solvent, reaction temperature, etc.] of this reaction are to be referred to those as explained in Process 1.

Process 4

The compound [Id] or its salt can be prepared by reacting a compound [V] or its salt with a compound [IV].

Suitable salts of the compounds [Id] and [V] may be the same as those exemplified for the compound [I].

This reaction can be carried out in substantially the same manner as Process 2, and therefore the reaction mode and reaction condition [e.g. solvent, reaction temperature, etc.] of this reaction are to be referred to those explained in Process 2.

Process 5

The compound [I] or its salt can be prepared by reacting a compound [VI] or its salt with a compound [VII] or its reactive derivative at the carboxy or sulfo group, or a salt thereof.

Suitable salt of the compound [VI] may be acid addition salt as exemplified for the compound [I].

Suitable salts of the compound [VII] and its reactive derivative at the carboxy or sulfo group may be metal salt or alkaline earth metal salt as exemplified for the compound [I].

This reaction can be carried out in substantially the same manner as Process 1, and therefore the reaction mode and reaction condition [e.g. solvent, reaction temperature, etc.] of this reaction are to be referred to those as explained in Process 1.

#### 10 Process 6

The compound [Ie] or its salt can be prepared by reacting a compound [VIII] or its reactive derivative at the carboxy group or sulfo group, or a salt thereof with a compound [IX] or its salt.

15 Suitable salts of the compounds [Ie], [VIII] and its reactive derivative at the carboxy or sulfo group may be the same as those exemplified for the compound [I].

Suitable salt of the compound [IX] may be acid addition salt as exemplified for the compound [I].

20 This reaction can be carried out in substantially the same manner as Process 1, and therefore the reaction mode and reaction condition [e.g. solvent, reaction temperature, etc.] of this reaction are to be referred to those as explained in Process 1.

25

#### Process 7

The compound [If] can be prepared by reacting a compound [X] or its salt with a compound [XI].

30 Suitable salts of the compounds [If] and [X] may be the same as those exemplified for the compound [I].

The present reaction is preferably carried out in the presence of base such as an alkali metal [e.g. lithium, sodium, potassium, etc.], alkaline earth metal [e.g. calcium, etc.], alkali metal hydride [e.g. sodium hydride, etc.],  
35 alkaline earth metal hydride [e.g. calcium hydride, etc.],

the hydroxide or carbonate or bicarbonate of an alkali metal or an alkaline earth metal [e.g. potassium bicarbonate, etc.] and the like.

This reaction is usually carried out in a solvent such as N,N-dimethylformamide, diethyl ether, tetrahydrofuran, dioxane, benzene, toluene, acetonitrile or any other solvent which does not adversely influence the reaction.

The reaction temperature is not critical, and the reaction is usually carried out under cooling to heating.

10

#### Process 8

The object compound [Ig] or its salt can be prepared by subjecting a compound [If] or its salt to elimination reaction of the N-protective group.

15        Suitable salts of the compounds [If] and [Ig] may be acid addition salts as exemplified for the compound [I].

This reaction is carried out in accordance with a conventional method such as hydrolysis, reduction or the like.

20        The hydrolysis is preferably carried out in the presence of a base or an acid including Lewis acid.

Suitable base may include an inorganic base and an organic base such as an alkali metal [e.g. sodium, potassium, etc.], an alkaline earth metal [e.g. magnesium, calcium, etc.], the hydroxide or carbonate or bicarbonate thereof, hydrazine, alkylamine [e.g. methylamine, trimethylamine, triethylamine, etc.], picoline, 1,5-diazabicyclo[4.3.0]non-5-ene, 1,4-diazabicyclo[2.2.2]octane, 1,8-diazabicyclo-[5.4.0]undec-7-ene, or the like.

30        Suitable acid may include an organic acid [e.g. formic acid, acetic acid, propionic acid, trichloroacetic acid, trifluoroacetic acid, etc.], an inorganic acid [e.g. hydrochloric acid, hydrobromic acid, sulfuric acid, hydrogen chloride, hydrogen bromide, hydrogen fluoride, etc.] and an acid addition salt compound [e.g. pyridine hydrochloride, 35        etc.].

The elimination using trihaloacetic acid [e.g. trichloroacetic acid, trifluoroacetic acid, etc.] or the like is preferably carried out in the presence of cation trapping agents [e.g. anisole, phenol, etc.].

5       The reaction is usually carried out in a solvent such as water, an alcohol [e.g. methanol, ethanol, etc.], methylene chloride, chloroform, tetrachloromethane, dioxane, tetrahydrofuran, a mixture thereof or any other solvent which does not adversely influence the reaction. A liquid base or  
10       acid can be also used as the solvent. The reaction temperature is not critical and the reaction is usually carried out under cooling to heating.

      The reduction method applicable for the elimination reaction may include chemical reduction and catalytic  
15       reduction.

      Suitable reducing agents to be used in chemical reduction are a combination of metal [e.g. tin, zinc, iron, etc.] or metallic compound [e.g. chromium chloride, chromium acetate, etc.] and an organic or inorganic acid [e.g. formic  
20       acid, acetic acid, propionic acid, trifluoroacetic acid, p-toluenesulfonic acid, hydrochloric acid, hydrobromic acid, etc.].

      Suitable catalysts to be used in catalytic reduction are conventional ones such as platinum catalysts [e.g. platinum  
25       plate, spongy platinum, platinum black, colloidal platinum, platinum oxide, platinum wire, etc.], palladium catalysts [e.g. spongy palladium, palladium black, palladium oxide, palladium on carbon, colloidal palladium, palladium on barium sulfate, palladium on barium carbonate, etc.], nickel  
30       catalysts [e.g. reduced nickel, nickel oxide, Raney nickel, etc.], cobalt catalysts [e.g. reduced cobalt, Raney cobalt, etc.], iron catalysts [e.g. reduced iron, Raney iron, etc.], copper catalysts [e.g. reduced copper, Raney copper, Ullman copper, etc.] and the like.

35       In case that the N-protective group is benzyl, the



reduction is preferably carried out in the presence of a combination of palladium catalysts [e.g. palladium black, palladium on carbon, etc.] and formic acid or its salt [e.g. ammonium formate, etc.].

5       The reduction is usually carried out in a conventional solvent which does not adversely influence the reaction such as water, methanol, ethanol, propanol, N,N-dimethylformamide, or a mixture thereof. Additionally, in case that the above-mentioned acids to be used in chemical reduction are in  
10 liquid, they can also be used as a solvent. Further, a suitable solvent to be used in catalytic reduction may be the above-mentioned solvent, and other conventional solvent such as diethyl ether, dioxane, tetrahydrofuran, etc. or a mixture thereof.

15       The reaction temperature of this reduction is not critical and the reaction is usually carried out under cooling to heating.

#### Process 9

20       The compound [Ii] or its salt can be prepared by reacting a compound [Ih] or its salt with a compound [XII].

Suitable salts of the compounds [Ih] and [Ii] may be the same as those exemplified for the compound [I].

25       This reaction can be carried out in substantially the same manner as Process 7, and therefore the reaction mode and reaction condition [e.g. solvent, reaction temperature, etc.] of this reaction are to be referred to those explained in Process 7.

#### 30   Process 10

The compound [Ij] or its salt can be prepared by reacting a compound [II] or its salt with a compound [XIII].

Suitable salts of the compounds [Ij] and [II] may be the same as those exemplified for the compound [I].

35       This reaction can be carried out in substantially the

same manner as Process 7, and therefore the reaction mode and reaction condition [e.g. solvent, reaction temperature, etc.] of this reaction are to be referred to those explained in Process 7.

5           The compounds obtained by the above processes can be isolated and purified by a conventional method such as pulverization, recrystallization, column chromatography, reprecipitation, or the like.

10           It is to be noted that the compound [I] and the other compounds may include one or more stereoisomer(s) such as optical isomer(s) or geometrical isomer(s) due to asymmetric carbon atom(s) and double bond(s), and all of such isomers and mixture thereof are included within the scope of this invention.

15           Additionally, it is to be noted that any solvate [e.g. enclosure compound (e.g. hydrate, etc.)] of the compound [I] or a pharmaceutically acceptable salt thereof is also included within the scope of this invention.

20           The object compound [I] and pharmaceutically acceptable salts thereof possess strong potentiation of the cholinergic activity, and are useful for the treatment and/or prevention of disorders in the central nervous system for mammals, and more particularly of amnesia, dementia (e.g., senile dementia, Alzheimer's dementia, dementia associated with various  
25 diseases such as cerebral vascular dementia, cerebral post-traumatic dementia, dementia due to brain tumor, dementia due to chronic subdural hematoma, dementia due to normal pressure hydrocephalus, post-meningitis dementia, Parkinson's disease type dementia, etc.) and the like. Additionally, the object  
30 compound is expected to be useful as therapeutical and/or preventive agents for schizophrenia, depression, stroke, head injury, nicotine withdrawal, spinal cord injury, anxiety, pollakiuria, incontinence of urine, myotonic dystrophy, attention deficit hyperactivity disorder, excessive daytime  
35 sleepiness (narcolepsy), Parkinson's disease or autism.

In order to illustrate the usefulness of the object compound [I], the pharmacological data of the compound [I] is shown in the following.

## 5 Test

### Penile erection in rat

(This test was carried out according to a similar manner to that described in Jpn. J. Pharmacol., Vol. 64, 147-153 (1994))

10

#### (i) Method

Male Fischer 344 rats at the age of 8 weeks (n=7) were used. All rats were handled 3 minutes a day for three successive days before the tests. The rats were tested in groups of seven and various doses of the test compound were given in semi-randomized order. The test compounds were suspended in 0.5% methyl-cellulose immediately before use, and given intraperitoneally in a volume of 1 ml/kg just before the start of test. Immediately after injection, each rat was placed in a perspex box (25x25x35 cm) and its behavior was observed for 60 minutes, during which time the number of penile erections was counted. A mirror was situated behind each box to facilitate of the rat. Data was expressed as a mean number.

25

#### (ii) Test Result

Test Compound (Example No.)	Dose (mg/kg)	Penile Erection (number/hr)
2	1	1.14
19	0.32	0.75

30

It is clear that the compound having the above-mentioned

activity ameliorates the memory deficits (i.e. amnesia, dementia, etc.) from the description in the Journal of Pharmacology and Experimental Therapeutics, Vo. 279, No. 3, 1157-1173 (1996). Further, it is expected that the compound  
5 having the above-mentioned activity is useful as  
therapeutical and/or preventive agent for aforesaid diseases from some patent applications (e.g. PCT International Publication No. WO 98/27930, etc.).

For therapeutic purpose, the compound [I] and a  
10 pharmaceutically acceptable salt thereof of the present  
invention can be used in a form of pharmaceutical preparation containing one of said compounds, as an active ingredient, in admixture with a pharmaceutically acceptable carrier such as an organic or inorganic solid, semi-solid or liquid excipient  
15 suitable for oral or parenteral administration. The  
pharmaceutical preparations may be capsules, tablets, dragees, granules, suppositories, solution, suspension, emulsion, or the like. If desired, there may be included in these  
preparations, auxiliary substances, stabilizing agents,  
20 wetting or emulsifying agents, buffers and other commonly  
used additives.

While the dosage of the compound [I] will vary depending upon the age and condition of the patient, an average single dose of about 0.1 mg, 1 mg, 10 mg, 50 mg, 100 mg, 250 mg, 500  
25 mg and 1000 mg of the compound [I] may be effective for  
treating the above-mentioned diseases. In general, amounts between 0.1 mg/body and about 1,000 mg/body may be administered per day.

30 The following Preparations and Examples are given for the purpose of illustrating this invention.

#### Preparation 1

To a solution of 1-benzyl-4-aminopiperidine (50 g) in  
35 water (360 ml) was added a solution of di-tert-butyl

dicarbonate (61 g) in acetone (360 ml) dropwise under cooling on an ice-water bath. After stirring for 2.5 hours, a precipitate was collected on a filter, washed with water, and dried. The crude product was poured into a mixture of  
5 diisopropyl ether (200 ml) and n-hexane (200 ml) and the mixture was stirred. After filtration, O-tert-butyl N-(1-benzylpiperidin-4-yl)carbamate (66.9 g) was obtained.

NMR (DMSO-d<sub>6</sub>,  $\delta$ ): 1.2-1.5 (2H, m), 1.37 (9H, s), 1.66  
(2H, br d, J=9.9Hz), 1.91 (2H, br t, J=10.7Hz),  
10 2.73 (2H, distorted d, J=11.8Hz), 3.2 (1H, m), 3.41  
(2H, s), 6.75 (1H, d, J=7.8Hz), 7.1-7.4 (5H, m)  
MASS (APCI) (m/z): 291

### Preparation 2

15 To a mixture of O-tert-butyl N-(1-benzylpiperidin-4-yl)carbamate (45 g) and 10% palladium on carbon (50% wet, 9 g) in methanol (1 l) was bubbled hydrogen gas under stirring at ambient temperature. The catalyst was removed by glass filter and the solvent was removed under reduced pressure.  
20 After rinse with diisopropyl ether, O-tert-butyl N-(piperidin-4-yl)carbamate (28.35 g) was obtained. The washed solvent was removed under reduced pressure, and the residue was rinsed with diisopropyl ether. The second fraction of O-tert-butyl N-(piperidin-4-yl)carbamate (344 mg)  
25 was obtained.

NMR (DMSO-d<sub>6</sub>,  $\delta$ ): 1.18 (2H, ddd, J=3.8, 11.8, 11.8Hz),  
1.37 (9H, s), 1.62 (2H, distorted d, J=10.8Hz),  
1.85 (1H, m), 2.38 (2H, dt, J=2.2, 12.0Hz), 2.86  
(2H, distorted d, J=12.3Hz), 3.2 (1H, m), 6.72 (1H,  
30 br d)  
MASS (APCI) (m/z): 201

### Preparation 3

To a suspension of O-tert-butyl N-(piperidin-4-yl)carbamate (4.0 g) in dichloromethane (40 ml) were added  
35

pyridine (1.94 ml), dichloromethane (40 ml), acetic anhydride (20.8 ml) and then N,N-dimethylaminopyridine (0.1 g) at ambient temperature. After stirring for 3 hours, the mixture was washed with 0.1N hydrochloric acid, water, and brine.

- 5 After drying with magnesium sulfate, the solvents were removed under reduced pressure. After rinse with diisopropyl ether, O-tert-butyl N-(1-acetylpiperidin-4-yl)carbamate (4.01 g) was obtained.

10 NMR (DMSO-d<sub>6</sub>, δ): 1.23 (2H, m), 1.38 (9H, s), 1.70 (2H, distorted t, J=11.4Hz), 1.97 (3H, s), 2.64 (1H, br t, J=11.1Hz), 3.04 (1H, dt, J=2.8, 11.5Hz), 3.42 (1H, m), 3.72 (1H, br d, J=15.0Hz), 4.19 (1H, br d, J=13.1Hz), 6.86 (1H, d, J=7.5Hz)

15 MASS (APCI) (m/z): 243

#### Preparation 4

- To a solution of O-tert-butyl N-(1-acetylpiperidin-4-yl)carbamate (2.42 g) in dichloromethane (24 ml) was added 4N hydrogen chloride in dioxane (24 ml). The solvents were removed under reduced pressure. After rinse with diisopropyl ether, 1-acetyl-4-aminopiperidine hydrochloride (2.02 g) was obtained.
- 20

25 NMR (DMSO-d<sub>6</sub>, δ): 1.41 (2H, m), 1.93 (2H, distorted t), 2.00 (3H, s), 2.60 (1H, br t, J=10.4Hz), 3.06 (1H, br t, J=11.3Hz), 3.12 (1H, m), 3.84 (1H, br d, J=14.0Hz), 4.34 (1H, br d, J=13.0Hz), 8.32 (3H, br s)

MASS (APCI) (m/z): 143

#### Preparation 5

- 30 To a solution of phenyl chloroformate (5.64 g) in dichloromethane (70 ml) was added a solution of 4-aminopyridine (2.84 g) and triethylamine (5.02 ml) in dichloromethane (100 ml) dropwise under cooling on an ice-water bath. After stirring for 1 hour, the solvents were
- 35

removed under reduced pressure. A residue was diluted with dichloromethane (200 ml) and water (200 ml). An organic phase was separated and washed with water and brine. After drying with magnesium sulfate, the solvents were removed under reduced pressure. The reaction mixture was diluted with diisopropyl ether and the precipitates were filtered. After rinse with diethyl ether, O-phenyl N-(4-pyridyl)carbamate (5.07 g) was obtained.

NMR (CDCl<sub>3</sub>,  $\delta$ ): 7.17 (2H, m), 7.27 (1H, m), 7.3-7.5

10 (4H, m), 8.50 (2H, dd, J=1.4, 5.0Hz), 8.06 (1H, s)

MASS (APCI) (m/z): 215

#### Preparation 6

A solution of sulfuryl chloride (3.55 ml) in chloroform (45 ml) was added a solution of 1-acetylpiperazine (5.66 mg) and triethylamine (6.16 ml) in chloroform (15 ml) dropwise under cooling on an ice-water bath. After stirring for 6 hours, a precipitate was collected by filtration. After drying over sodium hydroxide, 1-acetylpiperazine-4-sulfonyl chloride (2.43 g) was obtained.

NMR (CDCl<sub>3</sub>,  $\delta$ ): 2.15 (3H, s), 3.35 (4H, m), 3.69 (2H, t, J=5.1Hz), 3.83 (2H, br s)

MASS (APCI) (m/z): 227

#### 25 Preparation 7

To a solution of 1-benzyl-4-aminopiperidine (1.13 g) in dichloromethane (10 ml) were added a solution of 4-fluorobenzoyl chloride (0.99 g) in dichloromethane (1 ml) and diisopropylethylamine (1.09 ml) under cooling on an ice-water bath. The mixture was warmed to ambient temperature slowly under stirring. The mixture was diluted with dichloromethane and washed with water, saturated aqueous sodium hydrogen carbonate, water, and brine. After drying with magnesium sulfate, the solvents were removed under reduced pressure.

35 A residue was purified by column chromatography (silica gel

100 ml, dichloromethane:methanol = 15:1). After rinse with diisopropyl ether - n-hexane (1:1), N-(1-benzylpiperidin-4-yl)-4-fluorobenzamide (1.31 g) was obtained.

NMR (DMSO-d<sub>6</sub>, δ): 1.4-1.7 (2H, m), 1.7-1.9 (2H, m),  
5 2.01 (2H, br t, J=10.7Hz), 2.81 (2H, br d, J=11.6Hz), 3.46 (2H, s), 3.73 (1H, m), 7.2-7.4 (7H, m), 7.90 (2H, dd, J=5.6, 8.9Hz), 8.26 (1H, br d, J=7.7Hz)

MASS (APCI) (m/z): 313

10

#### Preparation 8

The following compound was obtained by using 4-amino-1-benzylpiperidine as a starting compound according to a similar manner to that of Example 2.

15

N-(1-Benzylpiperidin-4-yl)-N'-(4-fluorophenyl)urea

NMR (DMSO-d<sub>6</sub>, δ): 1.25-1.5 (2H, m), 1.7-1.9 (2H, m),  
2.0-2.2 (2H, m), 2.65-2.8 (2H, m), 3.4-3.6 (3H, m),  
6.07 (1H, d, J=7.6Hz), 7.05 (2H, t, J=9Hz), 7.2-  
20 7.45 (2H, m), 8.35 (1H, s)

MASS (APCI) (m/z): 328

#### Preparation 9

To a solution of N-(1-benzylpiperidin-4-yl)-N'-(4-fluorophenyl)urea (3.0 g) in a mixture of methanol (15 ml)  
25 and tetrahydrofuran (15 ml) was added palladium on carbon (10% w/w, 50% wet, 0.6 g), and the mixture was hydrogenated under atmospheric pressure of hydrogen for 8 hours. The catalyst was filtered off, and the solvents were evaporated  
30 under reduced pressure to give a residue, which was triturated with diisopropyl ether to give N-(piperidin-4-yl)-N'-(4-fluorophenyl)urea (1.97 g).

NMR (DMSO-d<sub>6</sub>, δ): 1.1-1.4 (2H, m), 1.65-1.85 (2H, m),  
2.3-2.65 (2H, m), 2.8-3.0 (2H, m), 3.3-3.7 (1H, m),  
35 6.08 (1H, d, J=8Hz), 7.04 (2H, t, J=9Hz), 7.25-7.5



NMR (DMSO-d<sub>6</sub>, δ): 1.1-1.4 (2H, m), 1.65-1.85 (2H, m),  
2.3-2.65 (2H, m), 2.8-3.0 (2H, m), 3.3-3.7 (1H, m),  
6.08 (1H, d, J=8Hz), 7.04 (2H, t, J=9Hz), 7.25-7.5  
(2H, m), 8.33 (1H, s)

5        MASS (APCI) (m/z): 238

#### Preparation 10

A mixture of N-(1-benzylpiperidin-4-yl)-4-fluorobenzamide (937 mg) and 10% palladium on carbon (50%  
10 wet, 0.2 g) in methanol (20 ml) was stirred under hydrogen atmosphere for 7.5 hours at ambient temperature. The catalyst was removed by glass filter and the solvent was removed under reduced pressure. After rinse with diisopropyl ether, N-(piperidin-4-yl)-4-fluorobenzamide (653  
15 mg) was obtained.

NMR (DMSO-d<sub>6</sub>, δ): 1.40 (2H, ddd, J=4.0, 11.9, 23.8Hz),  
1.72 (2H, br d, J=9.5Hz), 2.3-2.7 (2H, m), 2.8-3.2  
(2H, m), 3.80 (1H, m), 7.27 (2H, t, J=8.9Hz), 7.92  
(2H, dd, J=5.6, 8.9Hz), 8.26 (1H, d, J=7.7Hz)

20        MASS (APCI) (m/z): 223

#### Example 1

To a solution of O-phenyl N-(4-pyridyl)carbamate (446 mg) in 1,2-dichloroethane (5 ml) was added a suspension of  
25 1-acetylpiperazine (1.12 g) in 1,2-dichloroethane (20 ml) at ambient temperature. The mixture was heated at 60°C with stirring for 9 hours. The mixture was cooled to ambient temperature, and diluted with dichloromethane and water. The aqueous phase was separated and adjusted to pH 11.5 with  
30 sodium hydroxide solution. Excess sodium chloride was added to the aqueous solution. The mixture was extracted with a mixture of dichloromethane and methanol (about 10:1) and the organic phase was washed with brine. After drying with magnesium sulfate, the solvents were removed under reduced  
35 pressure. A residue was purified by column chromatography

(silica gel 100 ml, dichloromethane:methanol:aqueous ammonia = 10:1:0.1). After rinse with diisopropyl ether, 1-acetyl-4-(4-pyridylaminocarbonyl)piperazine (398 mg) was obtained.

5 NMR (DMSO-d<sub>6</sub>,  $\delta$ ): 2.03 (3H, s), 3.3-3.6 (8H, m), 7.47 (2H, dd, J=1.5, 4.8Hz), 8.31 (2H, dd, J=1.5, 4.8Hz), 9.01 (1H, s)

MASS (APCI) (m/z): 271

### Example 2

10 To a stirred solution of 1-acetylpiperazine (0.648 g) in tetrahydrofuran (10 ml) was added 4-fluorophenyl isocyanate (0.574 g) at ambient temperature. After stirring at ambient temperature for 1 hour, the solvent was removed by evaporation under reduced pressure, and the residue was  
15 triturated with diisopropyl ether to give 1-acetyl-4-(4-fluorophenylcarbamoyl)piperazine (1.25 g).

NMR (DMSO-d<sub>6</sub>,  $\delta$ ): 2.03 (3H, s), 3.3-3.6 (8H, m), 7.07 (2H, t, J=9Hz), 7.46 (2H, dd, J=5, 9Hz), 8.61 (1H, s)

20 MASS (APCI) (m/z): 266

### Example 3

The following compound was obtained by using 1-tert-butoxycarbonylpiperazine as a starting compound according to  
25 a similar manner to that of Example 2.

1-tert-Butoxycarbonyl-4-(4-fluorophenylcarbamoyl)-piperazine

30 NMR (DMSO-d<sub>6</sub>,  $\delta$ ): 1.42 (9H, s), 3.25-3.5 (8H, m), 7.07 (2H, t, J=9Hz), 7.45 (2H, dd, J=5, 9Hz), 8.60 (1H, s)

MASS (LD) (m/z): 346.2

### Example 4

35 To a solution of pyridine-4-carboxylic acid (1.0 g) and

triethylamine (1.2 ml) in toluene (20 ml) was added  
diphenylphosphoryl azide (1.75 ml) at ambient temperature.  
The resulting mixture was heated to reflux for 30 minutes  
and cooled to 0°C. To the mixture was added 1-tert-  
5 butoxycarbonylpiperazine (1.51 g), and the mixture was  
allowed to heat to 90°C for 1 hour. After cooling to ambient  
temperature, the reaction mixture was taken up into ethyl  
acetate, washed in turn with water and brine, dried over  
magnesium sulfate, and evaporated under reduced pressure.  
10 The residue was chromatographed on silica gel (150 ml)  
eluting with 0-7% methanol in dichloromethane. Trituration  
with a mixture of diisopropyl ether and ethanol gave 1-tert-  
butoxycarbonyl-4-(pyridin-4-ylcarbamoyl)piperazine (0.66 g).

NMR (DMSO-d<sub>6</sub>, δ): 1.42 (9H, s), 3.25-3.5 (8H, m), 7.46  
15 (2H, d, J=1.5, 5Hz), 8.30 (2H, d, J=1.5, 5Hz),  
9.00 (1H, s)

MASS (LD) (m/z): 307.2

#### Example 5

20 To a suspension of 1-acetyl-4-aminopiperidine  
hydrochloride (0.4 g) in dichloromethane (5 ml) were added  
in turn pyridine (0.54 ml) and 4-fluorophenyl chloroformate  
(0.29 ml) at 0°C. The mixture was allowed to warm to ambient  
temperature and stirred for 1 hour, which was taken up into  
25 a mixture of water and ethyl acetate. The separated organic  
layer was washed in turn with hydrochloric acid (1N),  
aqueous sodium hydrogen carbonate, and brine, and dried over  
magnesium sulfate. Evaporation under reduced pressure gave  
a residue, which was triturated with diisopropyl ether to  
30 give 1-acetyl-4-(4-fluorophenoxy carbonylamino)piperidine  
(347 mg).

NMR (DMSO-d<sub>6</sub>, δ): 1.15-1.55 (2H, m), 1.7-1.95 (2H, m),  
2.00 (3H, s), 2.65-2.85 (1H, m), 3.0-3.25 (1H, m),  
3.5-3.7 (1H, m), 3.7-3.9 (1H, m), 4.15-4.3 (1H, m),  
35 7.05-7.3 (4H, m), 7.86 (1H, d, J=8Hz)

MASS (APCI) (m/z): 281

Example 6

To a suspension of 1-acetyl-4-aminopiperidine  
5 hydrochloride (715 mg) in dichloromethane (7 ml) were added  
diisopropylethylamine (1.83 ml) and a solution of  
4-fluorobenzoyl chloride (0.83 mg) in dichloromethane (2 ml)  
at ambient temperature. After stirring for 6.5 hours, the  
reaction mixture was diluted with dichloromethane and washed  
10 with water, saturated aqueous sodium hydrogen carbonate, and  
brine. After drying with magnesium sulfate, the solvents  
were removed under reduced pressure. A residue was purified  
by column chromatography (silica gel 50 ml,  
dichloromethane:methanol = 50:1 to 10:1). After rinse with  
15 diisopropyl ether, N-(1-acetylpiperidin-4-yl)-4-  
fluorobenzamide (738 mg) was obtained.

NMR (DMSO-d<sub>6</sub>,  $\delta$ ): 1.40 (2H, m), 1.81 (2H, distorted t,  
J=12.4Hz), 2.01 (3H, s), 2.68 (1H, br t, J=11.4Hz),  
3.13 (1H, br t, J=11.6Hz), 3.83 (1H, br t,  
20 J=13.9Hz), 4.01 (1H, m), 4.33 (1H, br d, J=13.7Hz),  
7.29 (2H, t, J=8.9Hz), 7.92 (2H, dd, J=5.5, 8.8Hz),  
8.31 (1H, d, J=7.7Hz)

MASS (APCI) (m/z): 265

25 Example 7

To a suspension of 1-acetyl-4-aminopiperidine  
hydrochloride (536 mg) in dichloromethane (5 ml) were added  
isonicotinoyl chloride hydrochloride (534 mg) and  
diisopropylethylamine (1.05 ml) at ambient temperature.  
30 After stirring for 8 hours, the reaction mixture was poured  
into water and diluted with dichloromethane. The mixture  
was adjusted to pH 8.5 with 1N sodium hydroxide solution.  
Sodium chloride was added to the mixture and an organic  
phase was separated. The aqueous phase was extracted with  
35 dichloromethane and a combined organic phase was dried over

magnesium sulfate. The solvents were removed under reduced pressure. A residue was purified by column chromatography (silica gel 50 ml, dichloromethane:methanol = 10:1). After crystallization from diisopropyl ether:n-hexane,  
5 N-(1-acetylpiperidin-4-yl)-N-isonicotinamide (477 mg) was obtained.

NMR (DMSO-d<sub>6</sub>,  $\delta$ ): 1.4 (2H, m), 1.83 (2H, distorted t, J=11Hz), 2.01 (3H, s), 2.69 (1H, br t, J=11Hz),  
3.14 (1H, br t, J=12Hz), 3.83 (1H, br d, J=14.1Hz),  
10 4.03 (1H, m), 4.33 (1H, br d, J=13.1Hz), 7.75 (2H, dd, J=1.7, 4.4Hz), 8.62 (1H, d, J=7.5Hz), 8.72 (2H, dd, J=1.6, 4.4Hz)

MASS (APCI) (m/z): 248

#### 15 Example 8

To a suspension of 1-acetyl-4-aminopiperidine hydrochloride (715 mg) in dichloromethane (7 ml) were added diisopropylethylamine (1.83 ml) and a solution of 4-fluorobenzenesulfonyl chloride (0.83 mg) in  
20 dichloromethane (2 ml) at ambient temperature. After stirring for 6.5 hours, the reaction mixture was diluted with dichloromethane and washed with water, saturated aqueous sodium hydrogen carbonate, and brine. After drying  
25 reduced pressure. A residue was purified by column chromatography (silica gel 50 ml, dichloromethane:methanol = 50:1 to 20:1). After rinse with diisopropyl ether, N-(1-acetylpiperidin-4-yl)-4-fluorobenzenesulfonamide (859 mg) was obtained.

30 NMR (DMSO-d<sub>6</sub>,  $\delta$ ): 1.21 (2H, m), 1.54 (2H, m), 1.94 (3H, s), 2.66 (1H, br t, J=10.8Hz), 3.02 (1H, dt, J=2.9, 12.0Hz), 3.22 (1H, m), 3.64 (1H, br d, J=14.0Hz), 4.05 (1H, br d, J=13.2Hz), 7.44 (2H, t, J=8.9Hz), 7.8-8.0 (3H, m)

35 MASS (APCI) (m/z): 301

Example 9

To a solution of O-phenyl N-(4-pyridyl)carbamate (0.81 g) in chloroform (10 ml) were added 1-acetyl-4-aminopiperidine hydrochloride (0.68 g) and triethylamine (1.06 ml) at ambient temperature. After stirring for 1 day, the mixture changed to a solution. The solvents were removed under reduced pressure. A residue was purified by column chromatography (silica gel 100 ml, dichloromethane:methanol = 10:1 to 5:1, and silica gel 50 ml, dichloromethane:methanol:aqueous ammonia = 10:1:0.1). The solvents of desired fractions were removed under reduced pressure. A residue was dissolved with methanol (5 ml) and dichloromethane (5 ml), and 4N hydrogen chloride in dioxane (1.5 ml) was added to the solution. The solvents were removed under reduced pressure, and the residue was evaporated azeotropically with methanol. After crystallization from diisopropyl ether and n-hexane, N-(1-acetylpiperidin-4-yl)-N'-(4-pyridyl)urea (343 mg) was obtained.

NMR (DMSO-d<sub>6</sub>,  $\delta$ ): 1.1-1.6 (2H, m), 1.77 (2H, m), 2.01 (3H, s), 2.94 (1H, br t, J=10.4Hz), 3.22 (1H, br t, J=10.1Hz), 3.76 (2H, m), 4.05 (1H, d, J=13.6Hz), 7.60 (1H, d, J=7.8Hz), 7.83 (2H, d, J=6.8Hz), 8.52 (2H, d, J=7.1Hz), 11.21 (1H, s), 14.66 (1H, br s)

MASS (APCI) (m/z): 263

Example 10

To a suspension of 1-acetyl-4-aminopiperidine hydrochloride (536 mg) in dichloromethane (5 ml) were added 4-fluorophenyl isocyanate (375  $\mu$ l) and diisopropylethylamine (575  $\mu$ l) at ambient temperature. After stirring for 3 hours, the reaction mixture was diluted with dichloromethane. An organic phase was separated and an aqueous phase was extracted with dichloromethane. A combined organic phase was dried over magnesium sulfate and the solvents were

removed under reduced pressure. After crystallization from diisopropyl ether and n-hexane, N-(1-acetylpiperidin-4-yl)-N'-(4-fluorophenyl)urea (448 mg) was obtained.

5 NMR (DMSO-d<sub>6</sub>, δ): 1.1-1.5 (2H, m), 1.80 (2H, distorted t, J=10Hz), 2.00 (3H, s), 2.77 (1H, br d, J=10.8Hz), 3.14 (1H, br d, J=11.1Hz), 3.5-3.9 (2H, m), 4.16 (1H, br d, J=13.2Hz), 6.15 (1H, d, J=7.6Hz), 7.05 (2H, t, J=8.9Hz), 7.40 (2H, dd, J=5.0, 9.2Hz), 8.37 (1H, s)

10 MASS (APCI) (m/z): 280

#### Example 11

To a solution of 4-(4-fluorobenzoylamino)piperidine (0.25 g) in dichloromethane (5 ml) were added in turn  
15 pyridine (0.14 ml) and methyl chloroformate (87 μl) at 0°C. The mixture was allowed to warm to ambient temperature and stirred for 1 hour. To the mixture was added N,N-dimethylaminopyridine (0.13 g) and allowed to stir for another 1 hour. The reaction mixture was taken up into a  
20 mixture of water and ethyl acetate. The separated organic layer was washed in turn with hydrochloric acid (1N), aqueous sodium hydrogen carbonate, and brine, and dried over magnesium sulfate. Evaporation under reduced pressure gave a residue, which was triturated with diisopropyl ether to  
25 give 4-(4-fluorobenzoylamino)-1-methoxycarbonylpiperidine (0.265 g).

30 NMR (DMSO-d<sub>6</sub>, δ): 1.3-1.6 (2H, m), 1.75-1.9 (2H, m), 2.8-3.05 (2H, m), 3.60 (3H, s), 3.85-4.1 (2H, m), 7.29 (2H, t, J=9Hz), 7.90 (2H, dd, J=6, 9Hz), 8.30 (1H, d, J=8Hz)

MASS (APCI) (m/z): 281

#### Example 12

To a solution of 4-(4-fluorobenzoylamino)piperidine  
35 (0.25 g) in pyridine (5 ml) were added in turn

4-trifluorobenzenesulfonyl chloride (0.219 g) and catalytic amount of N,N-dimethylaminopyridine at 0°C.

The mixture was allowed to warm to ambient temperature and stirred for 1 hour, which was taken up into a mixture of

5 water and dichloromethane. The separated organic layer was washed in turn with hydrochloric acid (1N), aqueous sodium hydrogen carbonate, and brine, and dried over magnesium sulfate. Evaporation under reduced pressure gave a residue, which was triturated with diisopropyl ether to give  
10 4-(4-fluorobenzoylamino)-1-(4-trifluorophenylsulfonyl)-piperidine (0.38 g).

NMR (DMSO-d<sub>6</sub>, δ): 1.45-1.7 (2H, m), 1.8-1.95 (2H, m),  
2.35-2.55 (2H, m), 3.5-3.85 (3H, m), 7.28 (2H, t,  
J=9Hz), 7.50 (2H, t, J=9Hz), 7.75-7.95 (4H, m),  
15 8.31 (1H, d, J=8Hz)

MASS (APCI) (m/z): 381

### Example 13

To a solution of 4-(4-fluorobenzoylamino)piperidine  
20 (0.15 g) in dichloromethane (5 ml) were added in turn pyridine (82 µl) and 4-trifluoromethoxybenzoyl chloride (106 µl) at 0°C. The mixture was allowed to warm to ambient temperature and stirred for 4 hours, which was taken up into a mixture of water and dichloromethane. The separated  
25 organic layer was washed in turn with hydrochloric acid (1N), aqueous sodium hydrogen carbonate, and brine, and dried over magnesium sulfate. Evaporation of the solvent under reduced pressure gave 4-(4-fluorobenzoylamino)-1-(4-trifluoromethoxybenzoyl)piperidine (205 mg).

30 NMR (DMSO-d<sub>6</sub>, δ): 1.3-1.7 (2H, m), 1.7-2.0 (2H, m),  
2.7-3.4 (2H, m), 3.4-3.8 (1H, m), 3.9-4.2 (1H, m),  
4.2-4.6 (1H, m), 7.30 (2H, t, J=9Hz), 7.35-7.6 (4H,  
m), 7.91 (2H, dd, J=6, 9Hz), 8.35 (1H, d, J=8Hz)

MASS (LD) (m/z): 433.2



Example 14

To a solution of 4-(4-fluorobenzoylamino)piperidine (0.15 g) in dichloromethane (5 ml) were added in turn pyridine (0.14 ml) and methanesulfonyl chloride (96  $\mu$ l) at 0°C. The mixture was allowed to warm to ambient temperature and stirred for 1 hour. To the mixture was added N,N-dimethylaminopyridine (0.13 g) and allowed to stir for another 1 hour. The reaction mixture was taken up into a mixture of water and dichloromethane. The separated organic layer was washed in turn with hydrochloric acid (1N), aqueous sodium hydrogen carbonate, and brine, and dried over magnesium sulfate. Evaporation under reduced pressure gave a residue, which was triturated with diisopropyl ether to give 4-(4-fluorobenzoylamino)-1-methylsulfonylpiperidine (0.30 g).

NMR (DMSO- $d_6$ ,  $\delta$ ): 1.45-1.7 (2H, m), 1.8-2.05 (2H, m), 2.7-2.95 (2H, m), 2.88 (3H, s), 3.5-3.65 (2H, m), 3.8-4.05 (1H, m), 7.30 (2H, t,  $J=9$ Hz), 7.91 (2H, dd,  $J=6, 9$ Hz), 8.36 (1H, d,  $J=8$ Hz)

MASS (APCI) (m/z): 301

Example 15

To a solution of N-(piperidin-4-yl)-N'-(4-fluorophenyl)urea (0.3 g) in tetrahydrofuran (4 ml) were added in turn pyridine (0.28 ml), methyl chloroformate (98  $\mu$ l) and catalytic amount of N,N-dimethylaminopyridine at 0°C. The mixture was allowed to warm to ambient temperature and stirred for 2 hours. The reaction mixture was taken up into a mixture of water and ethyl acetate. The separated organic layer was washed in turn with hydrochloric acid (1N), aqueous sodium hydrogen carbonate, and brine, and dried over magnesium sulfate. Evaporation under reduced pressure gave a residue, which was triturated with diisopropyl ether to give N-(1-methoxycarbonylpiperidin-4-yl)-N'-(4-fluorophenyl)urea (0.312 g).

NMR. (DMSO- $d_6$ ,  $\delta$ ): 1.1-1.4 (2H, m), 1.7-1.9 (2H, m),  
2.8-3.1 (2H, m), 3.5-3.75 (1H, m), 3.59 (3H, s),  
3.75-3.95 (2H, m), 6.15 (1H, d,  $J=7.6\text{Hz}$ ), 7.05 (2H,  
t,  $J=9\text{Hz}$ ), 7.37 (2H, dd,  $J=5, 9\text{Hz}$ ), 8.37 (1H, s)

5      MASS (APCI) (m/z): 296

#### Example 16

To a solution of N-(piperidin-4-yl)-N'-(4-fluorophenyl)urea (0.3 g) in tetrahydrofuran (4 ml) were  
10 added in turn N,N-dimethylaminopyridine (0.23 g) and  
4-fluorobenzenesulfonyl chloride (0.25 g) at 0°C. The  
mixture was allowed to warm to ambient temperature and  
stirred for 1 hour. The reaction mixture was taken up into  
a mixture of water and dichloromethane. The separated  
15 organic layer was washed in turn with hydrochloric acid (1N),  
aqueous sodium hydrogen carbonate, and brine, and dried over  
magnesium sulfate. Evaporation under reduced pressure gave  
a residue, which was triturated with diisopropyl ether to  
give N-(1-(4-fluorophenylsulfonyl)-  
20 piperidin-4-yl)-N'-(4-fluorophenyl)urea (0.468 g).

NMR (DMSO- $d_6$ ,  $\delta$ ): 1.3-1.6 (2H, m), 1.75-1.95 (2H, m),  
2.45-2.7 (2H, m), 3.35-3.6 (3H, m), 6.14 (1H, d,  
 $J=7.5\text{Hz}$ ), 7.03 (2H, t,  $J=9\text{Hz}$ ), 7.34 (2H, dd,  $J=5,$   
9Hz), 7.50 (2H, t,  $J=9\text{Hz}$ ), 7.75-7.95 (2H, m), 8.31  
25 (1H, s)

MASS (APCI) (m/z): 396

#### Example 17

To a suspension of N-(piperidin-4-yl)-4-fluorobenzamide  
30 (0.5 g) in dichloromethane (5 ml) were added pyridine (218  
 $\mu\text{l}$ ), dichloromethane (5 ml) and benzoyl chloride (290  $\mu\text{l}$ ) at  
ambient temperature. After stirring for 3.5 hours, water (5  
ml) was poured into the mixture. An organic layer was  
separated, and washed with water and brine. After drying  
35 with magnesium sulfate, the solvents were removed under

reduced pressure. A residue was purified by column chromatography (silica gel, toluene:ethyl acetate = 1:1 to ethyl acetate). After rinse with diisopropyl ether, N-(1-benzoylpiperidin-4-yl)-4-fluorobenzamide (515 mg) was  
5 obtained.

NMR (DMSO-d<sub>6</sub>,  $\delta$ ): 1.50 (2H, br s), 1.85 (2H, br s),  
2.8-3.3 (2H, m), 3.61 (1H, m), 4.1 (1H, m), 4.35  
(1H, m), 7.29 (2H, t, J=8.9Hz), 7.3-7.5 (5H, m),  
7.92 (2H, dd, J=5.6, 8.9Hz), 8.34 (1H, d, J=7.9Hz)

10 MASS (APCI) (m/z): 327

#### Example 18

To a suspension of N-(piperidin-4-yl)-4-fluorobenzamide (556 mg) in dichloromethane (5 ml) were added pivaloyl  
15 chloride (0.37 ml), pyridine (0.24 ml) and  
N,N-dimethylaminopyridine (25 mg) at ambient temperature.  
After stirring for 1 day, the mixture was diluted with  
dichloromethane, and washed with water and brine. After  
drying with magnesium sulfate, the solvents were removed  
20 under reduced pressure. After trituration with diisopropyl  
ether, N-(1-pivaloylpiperidin-4-yl)-4-fluorobenzamide (305  
mg) was obtained.

NMR (DMSO-d<sub>6</sub>,  $\delta$ ): 1.20 (9H, s), 1.41 (2H, m), 1.7-1.9  
(2H, m), 2.91 (2H, br t, J=11.9Hz), 4.07 (1H, m),  
25 4.27 (2H, br d, J=13.3Hz), 7.29 (2H, t, J=8.9Hz),  
7.92 (2H, dd, J=5.5, 8.9Hz), 8.30 (1H, d, J=7.8Hz)

MASS (APCI) (m/z): 329

#### Example 19

30 To a suspension of N-(piperidin-4-yl)-4-fluorobenzamide  
(556 mg) in dichloromethane (6 ml) were added  
cyclopropanecarboxylic acid (0.20 ml), 1-  
hydroxybenzotriazole (338 mg) and 1-ethyl-3-(3-  
dimethylaminopropyl)carbodiimide hydrochloride (480 mg) at  
35 ambient temperature. After stirring for 21 hours, the

mixture was diluted with dichloromethane, and washed with water, saturated aqueous sodium hydrogen carbonate, and brine. After drying with magnesium sulfate, the solvents were removed under reduced pressure. After crystallization from diisopropyl ether, N-(1-cyclopropylcarbonylpiperidin-4-yl)-4-fluorobenzamide (627 mg) was obtained.

NMR (DMSO-d<sub>6</sub>,  $\delta$ ): 0.6-0.8 (4H, m), 1.2-1.6 (2H, m), 1.7-2.0 (2H, m), 1.85 (1H, m), 2.72 (1H, m), 3.21 (1H, m), 4.04 (1H, m), 4.30 (2H, m), 7.29 (2H, t, J=8.9Hz), 7.92 (2H, dd, J=5.6, 8.9Hz), 8.31 (1H, d, J=7.7Hz)

MASS (APCI) (m/z): 313

#### Example 20

1-tert-Butoxycarbonyl-4-(4-fluorophenylcarbamoyl)-piperazine (0.30 g) was dissolved in a solution of hydrogen chloride in ethyl acetate (4N, 2 ml), and the solution was stirred at ambient temperature for 1 hour. The solvent was removed by evaporation under reduced pressure to give 1-(4-fluorophenylcarbamoyl)piperazine as a white powder, which was taken up into dichloromethane (3 ml), and to the mixture were added in turn pyridine (0.25 ml), 4-trifluoromethoxybenzoyl chloride (0.146 ml), and catalytic amount of N,N-dimethylaminopyridine. After stirring at ambient temperature for 12 hours, the mixture was washed in turn with hydrochloric acid (0.5N), aqueous sodium hydrogen carbonate, and brine, dried over magnesium sulfate, and evaporated under reduced pressure. The residue was chromatographed on silica gel (50 ml) eluting with 0%-3% methanol in dichloromethane to give 1-(4-fluorophenylcarbamoyl)-4-(4-trifluoromethoxybenzoyl)-piperazine (0.19 g).

NMR (DMSO-d<sub>6</sub>,  $\delta$ ): 3.2-3.8 (8H, m), 7.08 (2H, t, J=9Hz), 7.35-7.5 (4H, m), 7.5-7.65 (2H, m)

MASS (LD) (m/z): 434.1

Example 21

The following compound was obtained by using methyl chloroformate as a reactive derivative at the carboxy group according to a similar manner to that of Example 20.

5

1-Methoxycarbonyl-4-(4-fluorophenylcarbamoyl)piperazine

NMR (DMSO-d<sub>6</sub>, δ): 3.3-3.5 (8H, m), 3.62 (3H, s), 7.07 (2H, t, J=9Hz), 7.44 (2H, dd, J=5, 9Hz), 8.62 (1H, s)

10

MASS (APCI) (m/z): 282

Example 22

A mixture of N-acetylpiperidine-4-carboxylic acid (514 mg), 1-hydroxybenzotriazole (405 mg), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (575 mg) and 4-fluoroaniline (284.2 ml) in dichloromethane (5 ml) was stirred for 18 hours at ambient temperature. The mixture was diluted with dichloromethane and washed with water, saturated aqueous sodium hydrogen carbonate, water, and brine. After drying with magnesium sulfate, the solvents were removed under reduced pressure. A residue was purified by column chromatography (silica gel 40 ml, dichloromethane:methanol = 15:1). After trituration with diisopropyl ether, 1-acetyl-4-(4-fluorophenyl)-carbamoylpiperidine (532 mg) was obtained.

NMR (DMSO-d<sub>6</sub>, δ): 1.3-1.7 (2H, m), 1.8 (2H, m), 2.01 (3H, s), 2.5 (2H, m), 3.05 (1H, br t, J=10.6Hz), 3.87 (1H, br d, J=14.1Hz), 4.40 (1H, br d, J=13.1Hz), 7.12 (2H, t, J=8.9Hz), 7.61 (2H, dd, J=5.1, 9.1Hz), 9.96 (1H, s)

30

MASS (APCI) (m/z): 265

Example 23

A solution of 1-acetylpiperazine-4-sulfonyl chloride (0.91 g) in chloroform (10 ml) were added 4-fluoroaniline

35

(0.38 ml) and triethylamine (0.56 ml) at ambient temperature.

After stirring for 6 days, the solvents were removed under reduced pressure. A residue was purified by column chromatography (silica gel 100 ml, dichloromethane:methanol = 19:1). After rinse with diisopropyl ether, 1-acetyl-4-(4-fluorophenyl)-sulfamoylpiperazine (716 mg) was obtained.

NMR (CDCl<sub>3</sub>,  $\delta$ ): 1.97 (3H, s), 3.09 (4H, m), 3.37 (4H, m), 7.20 (4H, m), 10.00 (1H, s)

10 MASS (APCI) (m/z): 302

#### Example 24

To a solution of O-tert-butyl (1-acetylpiperidin-4-yl)carbamate (0.97 g) in N,N-dimethylformamide (10 ml) was added 60% sodium hydride (0.18 g) at ambient temperature. After stirring for 40 minutes, 4-fluorobenzyl bromide (0.6 ml) was added to the reaction mixture. After additional stirring for 4 hours, the reaction mixture was poured into a mixture of ethyl acetate (50 ml) and water (10 ml). An organic phase was separated and washed with water and brine.

After drying with magnesium sulfate, the solvents were removed under reduced pressure. A residue was purified by column chromatography (silica gel 100 ml, toluene:ethyl acetate = 1:1 to 1:2). After crystallization from diisopropyl ether and n-hexane, O-tert-butyl N-(4-fluorobenzyl)-N-(1-acetylpiperidin-4-yl)carbamate (922 mg) was obtained.

NMR (DMSO-d<sub>6</sub>,  $\delta$ ): 1.35 (9H, br s), 1.3-1.8 (4H, m), 1.95 (3H, s), 2.3-2.6 (1H, m), 2.97 (1H, m), 3.80 (1H, br d, J=15.2Hz), 4.0 (1H, m), 4.32 (2H, s), 4.2-4.6 (1H, m), 7.0-7.4 (4H, m).

30 MASS (APCI) (m/z): 295

#### Example 25

35 To a solution of O-tert-butyl N-(4-fluorobenzyl)-N-(1-

acetylpiperidin-4-yl)carbamate (0.5 g) in dichloromethane (5 ml) was added 4N hydrogen chloride in dioxane (5 ml). The reaction mixture was diluted with diisopropyl ether and the precipitates were collected by filtration. After drying under reduced pressure, 1-acetyl-4-(4-fluorobenzyl)-aminopiperidine hydrochloride (409 mg) was obtained.

NMR (DMSO-d<sub>6</sub>+D<sub>2</sub>O,  $\delta$ ): 1.54 (2H, m), 2.02 (3H, s), 2.0-2.3 (2H, m), 2.4-2.7 (1H, m), 3.04 (1H, br t, J=12.1Hz), 3.29 (1H, m), 3.9 (1H, m), 4.17 (2H, s), 4.44 (1H, br d, J=13.6Hz), 7.27 (2H, t, J=8.9Hz), 7.66 (2H, br t, J=6.8Hz)

MASS (APCI) (m/z): 251

#### Example 26

To a solution of N-(1-acetylpiperidin-4-yl)-4-fluorobenzamide (529 mg) in N,N-dimethylformamide (5 ml) was added sodium hydride (0.1 g). After stirring for 45 minutes, methyl iodide (623 ml) was added to the solution. After stirring for 45 minutes, the mixture was diluted with ethyl acetate (100 ml) and water (50 ml). An organic phase was separated, and washed with water and brine. After drying with magnesium sulfate, the solvents were removed under reduced pressure. After trituration with diisopropyl ether, N-(1-acetylpiperidin-4-yl)-N-methyl-4-fluorobenzamide (248 mg) was obtained.

NMR (DMSO-d<sub>6</sub>,  $\delta$ ): 1.65 (4H, m), 2.00 (3H, s), 2.78 (3H, s), 3.8 (1H, m), 4.4 (1H, m), 2.0-4.6 (3H, br m), 7.26 (2H, t, J=8.9Hz), 7.46 (2H, dd, J=5.6, 8.7Hz)

MASS (APCI) (m/z): 301

#### Example 27

A suspension of 1-acetylpiperazine (0.627 g), 2-chloro-4'-fluoroacetophenone (0.844 g), and potassium hydrogen carbonate (0.735 g) in acetonitrile (12 ml) was stirred at

ambient temperature for 3 days. After removal of the solid by filtration, the filtrate was evaporated under reduced pressure to give a residue, which was chromatographed on silica gel (100 ml) eluting with 0%-5% methanol in

5 dichloromethane. The objective compound of the free form was taken up into ethyl acetate (2 ml) and to the solution was added a solution of hydrogen chloride in ethyl acetate (4N, 2 ml). The resulting precipitate was collected by filtration, washed with diisopropyl ether, and dried in  
10 vacuo to give 1-acetyl-4-(4-fluorophenylcarbonylmethyl)-piperazine hydrochloride (1.47 g).


NMR (DMSO-d<sub>6</sub>, δ): 2.06 (3H, s), 2.95-3.8 (6H, m), 3.9-4.15 (1H, m), 4.2-4.45 (1H, m), 5.13 (2H, s), 7.48 (2H, t, J=9Hz), 8.09 (2H, dd, J=5, 9Hz)

15 MASS (APCI) (m/z): 265



## C L A I M S

1. A compound of the formula:



wherein  $\text{R}^1$  is acyl,

$\text{R}^2$  is lower alkyl, lower alkoxy, lower  
alkylamino, lower alkenyl, lower  
alkenyloxy, lower alkenylamino, lower  
alkynyl, lower alkynyloxy, lower  
alkynylamino, cyclo(lower)alkyl,  
cyclo(lower)alkyloxy,  
cyclo(lower)alkylamino, aryl, aryloxy,  
arylamino, a heterocyclic group or amino  
substituted with a heterocyclic group,  
each of which may be substituted with  
suitable substituent(s); or acyl;

A is a single bond,  $\text{-}\overset{\text{O}}{\parallel}\text{C-}$  or  $\text{-SO}_2\text{-}$ ,

E is lower alkylene optionally substituted with  
suitable substituent(s),

X is CH or N,

Y is a single bond, lower alkylene or  $\text{-}\overset{\text{R}^5}{\underset{|}{\text{N}}}\text{-}$   
(wherein  $\text{R}^5$  is hydrogen, lower alkyl,  
substituted-lower alkyl, an N-protective  
group, aryl, acyl or a heterocyclic group),

Q is  $\text{-CH}_2\text{-}$ ,  $\text{-}\overset{\text{O}}{\parallel}\text{C-}$ ,  $\text{-SO}_2\text{-}$  or  $\text{-N=CH-}$ , and

$\text{R}^3$  and  $\text{R}^4$  are each hydrogen or lower alkyl, or  
are taken together to form lower alkylene  
optionally condensed with a cyclic  
hydrocarbon or a heterocyclic ring,

provided that when X is N,

then 1) Y is a single bond, and

Q is  $-\text{CH}_2-$ ,  $-\overset{\text{O}}{\underset{\parallel}{\text{C}}}-$  or  $-\text{SO}_2-$ , or

5

2) Y is lower alkylene,

and pharmaceutically acceptable salt thereof.

2. A compound according to claim 1, wherein

$\text{R}^2$  is aryl, aryloxy or arylamino, each aryl of which

10

may be substituted with halogen; pyridyl; or  
pyridylamino;

A is a single bond,

E is ethylene,

X is CH or N,

15

Y is a single bond, lower alkylene or  $-\overset{\text{R}^5}{\underset{|}{\text{N}}}-$

(wherein  $\text{R}^5$  is hydrogen, lower alkyl or  
an N-protective group),

Q is  $-\text{CH}_2-$ ,  $-\overset{\text{O}}{\underset{\parallel}{\text{C}}}-$  or  $-\text{SO}_2-$ , and

20

$\text{R}^3$  and  $\text{R}^4$  are taken together to form ethylene.

3. A compound according to claim 2, wherein

$\text{R}^1$  is lower alkanoyl, esterified carboxy, substituted  
or unsubstituted aroyl, lower alkylsulfonyl,  
substituted or unsubstituted arylsulfonyl, or  
cyclo(lower)alkylcarbonyl, and

25

$\text{R}^2$  is aryl or arylamino, each aryl of which may be  
substituted with halogen.

30

4. A compound according to claim 3, wherein

$\text{R}^1$  is lower alkanoyl, lower alkoxycarbonyl, aroyl,  
aroyl substituted with halo(lower)alkoxy, lower  
alkylsulfonyl, arylsulfonyl, arylsulfonyl  
substituted with halogen, or  
cyclo(lower)alkylcarbonyl,

35

X is CH,  
 Y is a single bond or  $\begin{array}{c} \text{H} \\ | \\ -\text{N}- \end{array}$ , and

5 Q is  $\begin{array}{c} \text{O} \\ || \\ -\text{C}- \end{array}$  or  $-\text{SO}_2-$ .

5. A compound according to claim 3, wherein  
 $\text{R}^1$  is lower alkanoyl, lower alkoxy carbonyl, aroyl,  
 10 aroyl substituted with halo(lower)alkoxy, lower  
 alkylsulfonyl, arylsulfonyl, arylsulfonyl  
 substituted with halogen, or  
 cyclo(lower)alkylcarbonyl,

X is N,  
 Y is a single bond or lower alkylene, and  
 15 Q is  $\begin{array}{c} \text{O} \\ || \\ -\text{C}- \end{array}$  or  $-\text{SO}_2-$ .

6. A compound according to claim 4, wherein

20 Y is  $\begin{array}{c} \text{H} \\ | \\ -\text{N}- \end{array}$ , and  
 Q is  $\begin{array}{c} \text{O} \\ || \\ -\text{C}- \end{array}$ .


7. A compound according to claim 5, wherein

25 Y is a single bond, and

Q is  $\begin{array}{c} \text{O} \\ || \\ -\text{C}- \end{array}$ .

8. A process for preparing a compound of the formula:

30



wherein  $\text{R}^1$  is acyl,

$R^2$  is lower alkyl, lower alkoxy, lower  
alkylamino, lower alkenyl, lower  
alkenyloxy, lower alkenylamino, lower  
alkynyl, lower alkynyloxy, lower  
alkynylamino, cyclo(lower)alkyl,  
cyclo(lower)alkyloxy,  
cyclo(lower)alkylamino, aryl, aryloxy,  
arylamino, a heterocyclic group or amino  
substituted with a heterocyclic group,  
each of which may be substituted with  
suitable substituent(s); or acyl;

A is a single bond,  $\overset{\text{O}}{\parallel}{\text{C}}$ - or  $\text{-SO}_2\text{-}$ ,

E is lower alkylene optionally substituted with  
suitable substituent(s),

X is CH or N,

Y is a single bond, lower alkylene or  $\overset{\text{R}^5}{\underset{|}{\text{N}}}\text{-}$   
(wherein  $\text{R}^5$  is hydrogen, lower alkyl,  
substituted-lower alkyl, an N-protective  
group, aryl, acyl or a heterocyclic group),

Q is  $\text{-CH}_2\text{-}$ ,  $\overset{\text{O}}{\parallel}{\text{C}}$ - ,  $\text{-SO}_2\text{-}$  or  $\text{-N=CH-}$ , and

$\text{R}^3$  and  $\text{R}^4$  are each hydrogen or lower alkyl, or  
are taken together to form lower alkylene  
optionally condensed with a cyclic  
hydrocarbon or a heterocyclic ring,

provided that when X is N,

then 1) Y is a single bond, and

Q is  $\text{-CH}_2\text{-}$ ,  $\overset{\text{O}}{\parallel}{\text{C}}$ - or  $\text{-SO}_2\text{-}$ , or

2) Y is lower alkylene,

or pharmaceutically acceptable salt thereof,  
which comprises,

1) reacting a compound of the formula:

5




or its salt with a compound of the formula:

10



or its reactive derivative at the carboxy or sulfo group, or a salt thereof to provide a compound of the formula:

15



or its salt, in the above formulas,

$\text{R}^1$ ,  $\text{R}^2$ ,  $\text{R}^3$ ,  $\text{R}^4$ , A and E are each as defined above, and

20

$\text{Q}_a$  is  $\text{-}\overset{\text{O}}{\parallel}\text{C-}$  or  $\text{-SO}_2\text{-}$ , or

2) reacting a compound of the formula:

25




or its salt with a compound of the formula:

30




to provide a compound of the formula:



or its salt, in the above formulas,  
 $R^1$ ,  $R^3$ ,  $R^4$ , A and E are each as defined above, and  
 $R^6$  is aryl which may be substituted with suitable  
 substituent(s); or pyridyl, or


3) reacting a compound of the formula:



or its salt with a compound of the formula:




or its reactive derivative at the carboxy or sulfo  
 group, or a salt thereof to provide a compound of the  
 formula:



or its salt, in the above formulas,  
 $R^1$ ,  $R^2$ ,  $R^3$ ,  $R^4$ , A, E and  $Q_a$  are each as defined above,  
 or


4) reacting a compound of the formula:



or its salt with a compound of the formula:




5 to provide a compound of the formula:




10 or its salt, in the above formulas,  
 $R^1$ ,  $R^3$ ,  $R^4$ ,  $R^6$ , A and E are each as defined above, or


5) reacting a compound of the formula:



or its salt with a compound of the formula:




or its reactive derivative at the carboxy or sulfo group, or a salt thereof to provide a compound of the formula:



or its salt, in the above formulas,  
 $R^1$ ,  $R^2$ ,  $R^3$ ,  $R^4$ , A, E, X, Y and Q are each as defined  
 30 above, or


6) reacting a compound of the formula:



or its reactive derivative at the carboxy or sulfo  
group, or a salt thereof with a compound of the  
formula:



or its salt to provide a compound of the formula:




or its salt, in the above formulas,

$\text{R}^1$ ,  $\text{R}^3$ ,  $\text{R}^4$ , A, E, X and  $\text{Q}_a$  are each as defined above,

and

$\text{R}^7$  is lower alkyl, lower alkenyl, lower alkynyl,  
cyclo(lower)alkyl, aryl or a heterocyclic group,  
each of which may be substituted with suitable  
substituent(s), or


7) reacting a compound of the formula:



or its salt with a compound of the formula:



to provide a compound of the formula:





or its salt, in the above formulas,

$R^1$ ,  $R^3$ ,  $R^4$ , A and E are each as defined above,


$R_a^5$  is an N-protective group,

$R_a^2$  is lower alkyl, lower alkenyl, lower alkynyl,  
 5 cyclo(lower)alkyl, aryl or a heterocyclic group,  
 each of which may be substituted with suitable  
 substituent(s),


$Q_b$  is  $-\text{CH}_2-$ ,  $-\overset{\text{O}}{\underset{\parallel}{\text{C}}}-$ ,  $-\text{SO}_2-$ , and

10  $Z_a$  is an acid residue, or

8) subjecting a compound of the formula:




or its salt to elimination reaction of the N-protective  
 group to provide a compound of the formula:



or its salt, in the above formulas,

25  $R^1$ ,  $R_a^2$ ,  $R^3$ ,  $R^4$ , A, E and  $Q_b$ , are each as defined above,  
 or

9) reacting a compound of the formula:




or its salt with a compound of the formula:

35



to provide a compound of the formula:



or its salt, in the above formulas,

$R^1$ ,  $R_a^2$ ,  $R^3$ ,  $R^4$ , A and E are each as defined above,

$Z_b$  is an acid residue,

$Q_C$  is  $\begin{array}{c} O \\ || \\ -C- \end{array}$ , and

$R_D^5$  is lower alkyl, or


10) reacting a compound of the formula:



or its salt with a compound of the formula:



to provide a compound of the formula:



or its salt, in the above formulas,

$R^1$ ,  $R^2$ ,  $R^3$ ,  $R^4$ , A, E and  $Q_a$  are each as defined above,

$Z_C$  is an acid residue, and

$Y_a$  is lower alkylene.

9. A pharmaceutical composition comprising a compound of claim 1, as an active ingredient, in association with a

pharmaceutically acceptable, substantially non-toxic carrier or excipient.

10. A compound of claim 1 for use as a medicament.

5

11. A method for therapeutic treatment and/or prevention of amnesia or dementia which comprises administering an effective amount of a compound of claim 1 to mammals.

10 12. Use of a compound of claim 1 for manufacture of a medicament for treating and/or preventing amnesia or dementia in mammals.

15

20

25

30

35

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/JP 00/00017

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D211/58 C07D213/75 C07D211/96 C07D295/20 C07D295/18  
C07D295/22 A61K31/445 A61K31/496 A61P25/28

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0 308 337 A (MITSUBISHI KASEI CORP.) 22 March 1989 (1989-03-22) page 4, line 15; claims	1-4, 9-12
X	EP 0 299 493 A (SHIONOGI & CO., LTD.) 18 January 1989 (1989-01-18) claims 1,5-10	1-3, 5, 9-12
X	WO 97 28141 A (PIERRE FABRE MEDICAMENT) 7 August 1997 (1997-08-07) examples 2, 5, 10, 11, 14, 26, 27, 28 claims 1,5,7-915-17	1-3, 5, 9-12
X	WO 97 17957 A (SMITHKLINE BEECHAM CORP.) 22 May 1997 (1997-05-22) page 6, compound 3 claims 1,5	1-4, 6, 9, 10
	-/--	

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

## \* Special categories of cited documents:

\*A\* document defining the general state of the art which is not considered to be of particular relevance

\*E\* earlier document but published on or after the international filing date

\*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

\*O\* document referring to an oral disclosure, use, exhibition or other means

\*P\* document published prior to the international filing date but later than the priority date claimed

\*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

\*&amp;\* document member of the same patent family

Date of the actual completion of the international search

7 April 2000

Date of mailing of the international search report

14/04/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Hass, C

International Application No  
PCT/JP 00/00017

PCT/JP 00/00017

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	DE 22 40 665 A (CHEMISCHE WERKE ALBERT AG) 7 March 1974 (1974-03-07) table 1, compounds 45-52 and 55-59 page 5, line 20 - line 25	1-3,5,9, 10
X	EP 0 002 401 A (SYNTHELABO) 13 June 1979 (1979-06-13) page 1, formula (I); page 15, compounds no. 15-19 claims 1,6	1-3,5,9, 10
X	WO 96 31501 A (SCHERING CORP.) 10 October 1996 (1996-10-10) page 71 -page 77; claims 1,6; examples 1-7,12	1-3,5,9, 10
X	DE 25 45 501 A (YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD.) 22 April 1976 (1976-04-22) page 9, formula; page 15, compound no. 102 claims 1,20	1-4,9,10
X	DE 23 11 570 A (JOHN WYETH & BROTHER LTD.) 13 September 1973 (1973-09-13) claims 1,5-7,9,14,27	1-4,9,10
X	EP 0 625 507 A (NISSHIN FLOUR MILLING CO., LTD.) 23 November 1994 (1994-11-23) claims 1,7,9; examples 94,128,129,131,133	1-7,9,10
X	WO 97 11069 A (FUJISAWA PHARMACEUTICAL CO., LTD.) 27 March 1997 (1997-03-27) claims 1,8,9	1-3,5,9, 10
X	EP 0 255 134 A (OTSUKA PHARMACEUTICAL CO., LTD.) 3 February 1988 (1988-02-03) table 1, reference examples no. 2-4; table 3, examples no. 20-22; table 6, examples no. 44, 45, 48, 49, 83, 84	1-6
X	CA 2 077 252 A (ACIC (CANADA) INC.) 1 March 1994 (1994-03-01) claims 9-12	1-3,5
X	EP 0 628 310 A (BAYER AG) 14 December 1994 (1994-12-14) page 6, line 40; example 1; table 1	1-4,6
X	US 3 647 805 A (T. IRIKURA ET AL.) 7 March 1972 (1972-03-07) claims 8,9,16	1-4,6
X	DE 19 38 512 A (KYORIN SEIYAKU K.K.) 14 January 1971 (1971-01-14) examples 12,24	1-4,6

-/-

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/JP 00/00017

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0 700 913 A (HOECHST-ROUSSEL PHARMACEUTICALS INC.) 13 June 1996 (1996-06-13) claim 10 ----	1-4
X	WO 94 22826 A (OTSUKA PHARMACEUTICAL CO., LTD.) 13 October 1994 (1994-10-13) claims 1,2,33-41 ----	1-3
X	US 5 723 490 A (R. D. TUNG) 3 March 1998 (1998-03-03) columns 25 and 26, compounds 227 and 229 ----	1
Y	WO 98 27930 A (FUJISAWA PHARMACEUTICAL CO., LTD.) 2 July 1998 (1998-07-02) cited in the application claims ----	1-3,5, 9-12
Y	WO 98 35951 A (FUJISAWA PHARMACEUTICAL CO., LTD.) 20 August 1998 (1998-08-20) cited in the application claims ----	1-3,5, 8-12
Y	EP 0 436 734 A (FUJISAWA PHARMACEUTICAL CO., LTD.) 17 July 1991 (1991-07-17) claims & WO 91 01979 A cited in the application ----	1-3,5, 8-12
Y	WO 98 25914 A (FUJISAWA PHARMACEUTICAL CO., LTD.) 18 June 1998 (1998-06-18) claims 1,4-7 ----	1-3,5, 9-12
A	US 5 346 907 A (J. F. KERWIN ET AL.) 13 September 1994 (1994-09-13) claims 1,4-6; examples 61,62,94-116 -----	1,9-12

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP 00/00017

### Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 11  
because they relate to subject matter not required to be searched by this Authority, namely:  
Remark: Although claim 11  
is directed to a method of treatment of the human/animal  
body, the search has been carried out and based on the alleged  
effects of the compound/composition.
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such  
an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

### Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all  
searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment  
of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report  
covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is  
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/JP 00/00017

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
EP 308337	A	22-03-1989	JP 1075484 A	22-03-1989
			JP 1966859 C	18-09-1995
			JP 6096575 B	30-11-1994
			AT 77389 T	15-07-1992
			CA 1320310 A	13-07-1993
			DE 3872127 A	23-07-1992
			HU 47928 A	28-04-1989
			KR 9711296 B	09-07-1997
			US 4880819 A	14-11-1989
EP 299493	A	18-01-1989	AT 106868 T	15-06-1994
			AU 608025 B	21-03-1991
			CA 1322199 A	14-09-1993
			DE 3889987 D	14-07-1994
			DE 3889987 T	15-09-1994
			DK 393488 A	16-01-1989
			ES 2056860 T	16-10-1994
			JP 1104041 A	21-04-1989
			JP 2552905 B	13-11-1996
			KR 9006742 B	20-09-1990
			US 4904663 A	27-02-1990
WO 9728141	A	07-08-1997	FR 2744449 A	08-08-1997
			AU 1607497 A	22-08-1997
			BR 9707251 A	06-04-1999
			CN 1214047 A	14-04-1999
			EP 0880512 A	02-12-1998
WO 9717957	A	22-05-1997	EP 0873117 A	28-10-1998
			JP 2000500465 T	18-01-2000
DE 2240665	A	07-03-1974	DE 2157424 A	24-05-1973
			AT 336625 B	10-05-1977
			AT 469674 A	15-09-1976
			AT 327207 B	26-01-1976
			AT 469774 A	15-04-1975
			AT 336626 B	10-05-1977
			AT 327203 B	26-01-1976
			AT 981272 A	15-04-1975
			BE 791501 A	17-05-1973
			CA 1025866 A	07-02-1978
			CH 613202 A	14-09-1979
			CH 612430 A	31-07-1979
			CH 592080 A	14-10-1977
			CH 590265 A	29-07-1977
			ES 408565 A	01-11-1975
			FR 2160611 A	29-06-1973
			GB 1407854 A	24-09-1975
			JP 1004705 C	30-06-1980
			JP 52053871 A	30-04-1977
			JP 54040555 B	04-12-1979
			JP 52053872 A	30-04-1977
			JP 55019219 B	24-05-1980
			JP 52053873 A	30-04-1977
			JP 57060350 B	18-12-1982
			JP 1032329 C	29-01-1981
			JP 48061484 A	28-08-1973
			JP 55023831 B	25-06-1980



# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/JP 00/00017

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
DE 2240665	A		NL 7215416 A,B, SE 408423 B US 4374990 A US 4115569 A AT 923274 A	22-05-1973 11-06-1979 22-02-1983 19-09-1978 15-09-1976
EP 2401	A	13-06-1979	FR 2409994 A FR 2439195 A AR 225604 A AT 366679 B AT 840578 A AU 517219 B AU 4188478 A CA 1101858 A DK 519678 A ES 475299 A FI 783586 A GR 65321 A IE 47677 B IL 56021 A IT 1101422 B JP 1317177 C JP 54081280 A JP 60039273 B MX 5009 E NO 783933 A NZ 188982 A PT 68821 A US 4243665 A ZA 7806553 A	22-06-1979 16-05-1980 15-04-1982 26-04-1982 15-09-1981 16-07-1981 31-05-1979 26-05-1981 25-05-1979 16-04-1979 25-05-1979 11-08-1980 16-05-1984 13-09-1981 28-09-1985 15-05-1986 28-06-1979 05-09-1985 14-02-1983 28-05-1979 05-03-1980 01-12-1978 06-01-1981 31-10-1979
WO 9631501	A	10-10-1996	AU 5432696 A CA 2217351 A EP 0820452 A JP 10511979 T ZA 9602694 A	23-10-1996 10-10-1996 28-01-1998 17-11-1998 03-10-1996
DE 2545501	A	22-04-1976	JP 51052176 A AU 8564375 A BE 834247 A FR 2287228 A NL 7511857 A SE 7511408 A	08-05-1976 21-04-1977 02-02-1976 07-05-1976 14-04-1976 13-04-1976
DE 2311570	A	13-09-1973	GB 1416872 A AU 467944 B AU 5242173 A BE 855713 A CH 576964 A CH 577476 A FR 2181807 A HK 10279 A JP 1283088 C JP 49000273 A JP 60004187 B KE 2916 A US 3971787 A US 3971789 A	10-12-1975 18-12-1975 17-10-1974 03-10-1977 30-06-1976 15-07-1976 07-12-1973 09-03-1979 27-09-1985 05-01-1974 01-02-1985 30-03-1979 27-07-1976 27-07-1976

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/JP 00/00017

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
DE 2311570	A		IN 138602 A	28-02-1976
EP 625507	A	23-11-1994	CA 2123728 A	22-11-1994
			DE 69404382 D	04-09-1997
			DE 69404382 T	05-03-1998
			JP 7258200 A	09-10-1995
			US 5621010 A	15-04-1997
WO 9711069	A	27-03-1997	AU 6999796 A	09-04-1997
			EP 0861243 A	02-09-1998
			US 6008229 A	28-12-1999
EP 255134	A	03-02-1988	JP 2025271 C	26-02-1996
			JP 7045493 B	17-05-1995
			JP 64003182 A	06-01-1989
			JP 1964561 C	25-08-1995
			JP 6096555 B	30-11-1994
			JP 63035562 A	16-02-1988
			DE 3784401 A	08-04-1993
			DK 397387 A	01-02-1988
			ES 2053480 T	01-08-1994
			US 4886809 A	12-12-1989
			US 5071856 A	10-12-1991
			US 5306719 A	26-04-1994
CA 2077252	A	01-03-1994	AU 4938593 A	29-03-1994
			WO 9405628 A	17-03-1994
			EP 0656885 A	14-06-1995
			US 5686612 A	11-11-1997
			US 5675006 A	07-10-1997
EP 628310	A	14-12-1994	DE 4319038 A	15-12-1994
			JP 7330761 A	19-12-1995
			US 5492918 A	20-02-1996
US 3647805	A	07-03-1972	NONE	
DE 1938512	A	14-01-1971	JP 49039679 B	28-10-1974
			BE 736840 A	31-12-1969
			CA 931574 A	07-08-1973
			CA 958717 A	03-12-1974
			CA 948203 A	28-05-1974
			DE 1967324 C	22-04-1982
			ES 369746 A	01-04-1971
			ES 378466 A	16-06-1972
			ES 378467 A	16-06-1972
			FR 2048024 A	19-03-1971
			GB 1276812 A	07-06-1972
			GB 1276813 A	07-06-1972
EP 700913	A	13-03-1996	US 5500423 A	19-03-1996
			AT 166876 T	15-06-1998
			CA 2157860 A	10-03-1996
			DE 69502783 D	09-07-1998
			DE 69502783 T	12-11-1998
			ES 2118483 T	16-09-1998
			JP 8092251 A	09-04-1996
			US 5563272 A	08-10-1996

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/JP 00/00017

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9422826	A	13-10-1994	AU 674207 B	12-12-1996
			AU 6292894 A	24-10-1994
			CA 2136999 A	13-10-1994
			CN 1104412 A	28-06-1995
			EP 0650476 A	03-05-1995
			JP 2825755 B	18-11-1998
			JP 6340627 A	13-12-1994
			US 5656642 A	12-08-1997
			US 5760058 A	02-06-1998
US 5723490	A	03-03-1998	US 5783701 A	21-07-1998
			US 5585397 A	17-12-1996
			AU 706732 B	24-06-1999
			AU 5559696 A	07-11-1996
			BG 102048 A	31-08-1998
			BR 9608032 A	12-01-1999
			CA 2217737 A	24-10-1996
			CN 1181755 A	13-05-1998
			CZ 9703293 A	18-03-1998
			EP 0846110 A	10-06-1998
			HU 9801877 A	28-09-1999
			JP 10509739 T	22-09-1998
			NO 974722 A	13-10-1997
			PL 322877 A	02-03-1998
			SK 143197 A	08-04-1998
			WO 9633184 A	24-10-1996
			US 5977137 A	02-11-1999
			US 5856353 A	05-01-1999
			AP 390 A	02-08-1995
			AT 178598 T	15-04-1999
			AU 691160 B	14-05-1998
			AU 4852093 A	29-03-1994
			BG 62488 B	30-12-1999
			BG 99540 A	30-11-1995
			BR 1100824 A	31-08-1999
			CA 2143208 A	17-03-1994
			CN 1087347 A	01-06-1994
			CZ 9500587 A	13-12-1995
			DE 69324369 D	12-05-1999
			DE 69324369 T	26-08-1999
			EP 0659181 A	28-06-1995
			EP 0885887 A	23-12-1998
			ES 2131589 T	01-08-1999
			FI 951059 A	18-04-1995
			GR 3030719 T	30-11-1999
			HU 71892 A	28-02-1996
			JP 8501299 T	13-02-1996
			LT 917 A,B	25-11-1994
			NO 950876 A	08-05-1995
			NZ 256238 A	24-04-1997
			NZ 314376 A	28-10-1998
			PL 307858 A	26-06-1995
			SG 43862 A	14-11-1997
			SK 29395 A	13-09-1995
			WO 9405639 A	17-03-1994
WO 9827930	A	02-07-1998	EP 0942726 A	22-09-1999

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/JP 00/00017

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9835951 A	20-08-1998	EP 0968201 A	05-01-2000
EP 436734 A	17-07-1991	DE 69022965 D	16-11-1995
		DE 69022965 T	04-04-1996
		DK 436734 T	20-11-1995
		HK 64196 A	19-04-1996
		WO 9101979 A	21-02-1991
		JP 2531304 B	04-09-1996
		US 5250528 A	05-10-1993
WO 9825914 A	18-06-1998	AU 5136898 A	03-07-1998
		EP 0944612 A	29-09-1999
US 5346907 A	13-09-1994	EP 0336356 A	11-10-1989
		EP 0442878 A	28-08-1991
		JP 3503650 T	15-08-1991
		WO 8910355 A	02-11-1989
		CA 2062755 A	08-01-1991
		EP 0480969 A	22-04-1992
		GR 90100516 A,B	10-12-1991
		JP 4506660 T	19-11-1992
		PT 94623 A	20-03-1991
		WO 9100725 A	24-01-1991